Author: Editor

By. Yennifer Chan, MD Lisa Yen, MD Courtesy: LACNETS Date. 11/09/2023 Cabozantinib in the CABINET Trial: NET Results Lisa Yen, MD, the Director of Programs and Outreach at ESMO 2023 in Madrid, is alongside Dr. Jennifer Chan, the Principal Investigator of the Alliance Phase Three Study. This study, known as the Cabinet Study, explores Cabozantinib’s efficacy compared to a placebo in Advanced Neuroendocrine Tumors after prior therapy. Dr. Chan recently revealed the trial’s outcomes, demonstrating the effectiveness of Cabozantinib in both cohorts of patients. The results showed an improvement in progression-free survival for those receiving Cabozantinib compared…

By: Dr. Rahul Gusain, MD Dr. Rohit Gusain, MD Dr. Joshua Reuss, MD Date: 11/07/2023 Courtesy: OncologyBrothers Drs. Rahul Gosain, MD and Rohit Gosain, MD, referred to as the oncology brothers, reflected on the impressive content presented at ESMO 2023. They segmented the lung cancer highlights into two key studies: KEYNOTE 671 focusing on resectable non-small cell lung cancer and the Alina trial for ALK-positive patients. They were joined by Dr. Joshua Reuss from Georgetown Lombardi Kansas Center. KEYNOTE 671 Results from ESMO 2023 KEYNOTE 671, a phase 3 study, examined the peroperative IO…

The full video from the Spanish Targeted Therapies in Lung Cancer Patient Forum 2023 is available now to view ONDemand, while we edit and produce smaller videos by topic. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Aakash Desai discusses the current recommendations for biomarker testing in patients with NSCLC, as well as best practices. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Aakash Desai gives a basic overview of biomarkers and discusses which ones are important for patients with NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Aakash Desai details the importance of biomarker testing and discusses the method of liquid biopsy to do so. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

This full unedited version of the 2023 Targeted Therapies in Lung Cancer Patient Forum presentations from the Mainstage, on Saturday, July 15, 2023 is now available OnDemand. These topics will be edited and offered as shorter videos in the coming weeks. For the breakout presentations from the 2nd Stage, please see: https://youtu.be/XITX_YhElIE For more, please visit http://cancerGRACE.org/. To ask a question, visit https://cancergrace.org/forum.

This full unedited version of the 2023 Targeted Therapies in Lung Cancer Patient Forum presentations from the Mainstage, on Saturday, July 15, 2023 is now available OnDemand. These topics will be edited and offered as shorter videos in the coming weeks. For the full mainstage presentations please see: https://youtu.be/v85bJi-vtGM For more, please visit http://cancerGRACE.org/. To ask a question, visit https://cancergrace.org/forum.

By: Byoung Chul Cho, MD, PhD, Yonsei University, Seoul, Korea, Date: 11/03/2023 Courtesy: VJOncology Above is a video from Byoung Chul Cho, MD, PhD, Yonsei University, Seoul, Korea about the MARIPOSA Phase 3 trial a randomized study comparing amivantamab plus lazertinib compared to osimertinib in advanced EGFR mutated lung cancer. During this ESMO 2023, the primary and some secondary endpoints of the MARIPOSA study were presented. The primary endpoint of the MARIPOSA study aimed to evaluate the progression-free survival (PFS) of amivantamab plus lazertinib compared to osimertinib according to RECIST version 1.1. The secondary endpoints included overall survival, duration of…

By. Stuart McIntosh, MDDate. November 03, 2023Stuart McIntosh, MD, Chief Medical Officer, initiated a study in the field of oncology. His work involved combining samuraciclib, a CDK7 inhibitor, with elacestrant, an oral Selective Estrogen Receptor Degrader (SERD), specifically for patients with CDK4/6 inhibitor-resistant HR+, HER2- metastatic breast cancer.The study aimed to address resistance to CDK4/6 inhibitors in this specific patient subset. McIntosh’s research sought to explore the benefits of this combination therapy, focusing on efficacy, safety, and tolerability.The investigation explored the risks and benefits linked with the combination therapy. Early findings indicated potential therapeutic advantages in managing resistance in this…

By. Mohammed Dar, MDDate. November 02, 2023Mohammed Dar, MD, observed significant advancements in the treatment of metastatic uveal melanoma, particularly for HLA-A02:01 positive patients with the introduction of tebentafusp (TA BENT A FUSP). In comparison to the control group, tebentafusp demonstrated notable improvements in overall survival rates. The specific data revealed a substantial increase in survival rates among patients receiving tebentafusp compared to those in the control group. This has a significant impact on the current standard of care for HLA-A02:01 positive patients, potentially reshaping treatment protocols for this subgroup.Regarding early survival benefits, the first six weeks of tebentafusp treatment…

By. Corina Dutcus, MDDate. November 02, 2023Corina Dutcus, MD, a lead investigator in the Phase 3 LEAP-014 trial for metastatic esophageal squamous cell carcinoma, presented insights into the trial’s objectives, findings, and implications for patient care.The Phase 3 LEAP-014 trial aimed to evaluate the efficacy and safety of combining lenvatinib, pembrolizumab, and chemotherapy for this cancer type, focusing on overall survival, progression-free survival, and safety measures.Dr. Dutcus summarized the trial findings, noting improvements in overall survival, progression-free survival, and a manageable safety profile for the combination therapy.The addition of lenvatinib and pembrolizumab to chemotherapy represents a significant advancement in the…

By. Tyler Ames, PhDDate. November 01, 2023Tyler Ames, Ph.D. in oncology research, delves into the intricate mechanisms of PT-112’s impact on cancer cells and its potential significance in treating metastatic castration-resistant prostate cancer and thoracic malignancies.Addressing the significance of PT-112’s ability to release damage-associated molecular patterns (DAMPs) and induce immunogenic cell death (ICD), Dr. Ames underscores their pivotal role in the immune system’s response against cancer. The release of DAMPs triggers an immune response, alerting the body to recognize and target cancerous cells, particularly crucial in metastatic and castration-resistant prostate cancer and thoracic malignancies.When exploring the early molecular effects of…

By. Aditya Bardia, MDDate. November 01, 2023 Dr. Aditya Bardia, an oncologist specializing in breast cancer treatment, provided insights into the NATALEE trial, presenting pivotal data at ESMO 2023. The trial, under his leadership, aimed to advance breast cancer therapy and contribute significantly to understanding treatment modalities. Dr. Bardia’s contributions to the trial and subsequent findings established him as a prominent figure in advancing breast cancer research. The NATALEE trial had specific objectives, focusing on improving outcomes for patients with HER2-positive early breast cancer. It investigated the effectiveness of dual HER2 blockade (using two anti-HER2 agents) in combination with chemotherapy…

By. Corina Dutcus, MDDate. November 01, 2023Corina Ductus, MD, a medical doctor and the Senior Vice President of Clinical Development at Eisai, recently addressed critical aspects of the Phase 3 Study 309/KEYNOTE-775 trial focusing on patients with advanced endometrial cancer. The trial specifically evaluated the efficacy of pembrolizumab in combination with lenvatinib for patients who had undergone prior platinum therapy.During the interview, Dr. Ductus discussed the key findings from the trial. The research showcased significant improvements in progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). These statistically and clinically significant enhancements in patient outcomes hold immense significance…

Author: Dr Antonio Passaro (on-camera comments) – Courtesy of ESMO.org At the ESMO 2023 conference, the results of the Phase three global randomized Mariposa 2 trial were presented. The trial focused on patients with advanced non-small cell lung cancer after progressing on Ozimertinib due to an EGFR mutation. The study aimed to evaluate Amivantamab combined with chemotherapy, with or without Lazertinib, compared to standard chemotherapy. The trial involved 657 patients from various regions and aimed to assess progression-free survival. The primary endpoint was to compare the survival benefits among the different treatment arms. The study found a statistically significant improvement in…

Author: Dr. Yelena Janjigian (on-camera comments) – Courtesy of ESMO.org The Matterhorn study, a significant phase three global research effort, aims to determine the efficacy of a triplet regimen involving chemotherapy with flood alongside durvalumab in treating early-stage non-metastatic gastric and gastroesophageal adenocarcinoma. Presented at ESMO 2023, the study’s first interim analysis involved nearly 1000 patients from various regions globally, utilizing a randomized approach of flood plus durvalumab or placebo. Results revealed a 12% enhancement in complete response rate and a 15% improvement in node negativity status, which is crucial for clinical outcomes. While the study successfully met its interim…

By. Antonio Passaro, MDDate. October 31, 2023Antonio Passaro, MD, an oncologist specializing in lung cancer, has been deeply involved in the analysis and interpretation of the Phase 3 MARIPOSA-2 study. The primary objective of this pivotal trial was to investigate the efficacy and safety of the amivantamab regimen, in combination with chemotherapy, for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring specific EGFR mutations.The study’s key findings have been groundbreaking, revealing a significant advancement in the treatment landscape for NSCLC. Dr. Passaro highlights the remarkable results that demonstrate a 56% and 52% reduction in the risk…

By. Noura Choudhury, MD Date. October 31, 2023Noura Choudhury, MD, a medical researcher specializing in oncology therapeutics, is a key figure in understanding the clinical significance of HPN328, a cutting-edge immunotherapy drug. Her expertise and experience in the field enable a comprehensive analysis of recent clinical trial data and its implications for cancer treatment.In the interview, Dr. Noura Choudhury addresses the significant insights drawn from HPN328’s clinical trial results. Highlighting the drug’s remarkable confirmed response rate of 35% across diverse tumor types with a mere 1 mg priming dose, including instances of complete responses, she elucidates the potential implications for…

By. Mohamed H. Derbala, MDDate. October 31, 2023Mohamed H. Derbala, MD, an immuno-oncology expert and a Research Scientist at MD Anderson Cancer Center, is slated to share his expertise during an exclusive interview. The discussion will revolve around pivotal inquiries concerning TIGIT and its implications in immunotherapy.The interview will provide a comprehensive exploration of various critical facets related to TIGIT. Dr. Derbala will delve into the intricate role that TIGIT plays in immune suppression, shedding light on its function as an inhibitory receptor impacting immune cells such as T cells and natural killer (NK) cells. His extensive research and findings…

By. Corina Dutcus, MDDate. October 30, 2023In this video interview, Corina Dutcus, MD, will address pivotal aspects of phase 3 CLEAR study, focusing on the combination of lenvatinib and pembrolizumab in the treatment of advanced clear cell renal cell carcinoma (ccRCC). She will dive into the key findings and their implications for clinical practice.Dr. Dutcus will highlight the study’s pivotal results, emphasizing the better objective response rate (ORR) achieved with the lenvatinib and pembrolizumab combination compared to sunitinib. She will explain the significance of ORR in this context, elucidating its role as a metric in evaluating treatment efficacy.Furthermore, the discussion…

Author: Dr Michiel van der Heijden (on-camera comments) – Courtesy of ESMO.org Checkmate 901, a study focusing on first-line treatment for metastatic or irresectable urothelial cancer patients, aimed to improve existing chemotherapy approaches. Traditionally, chemotherapy, primarily cisplatin or gemcitabine, has been the standard for such cases. With the recent introduction of immunotherapy, there has been a challenge as many patients were unable to transition to immunotherapy post-chemotherapy. Involving around 600 patients, the study randomized participants into two groups: one receiving the standard cisplatin-gemcitabine and the other receiving this combination along with nivolumab, a checkpoint inhibitor. The trial successfully met its…

Dr Laurence Albiges (on-camera comments) – Courtesy of ESMO.org During ESMO 2023, an individual presented a study at the forefront of oncology research. The study, known as LITESPARK-005, focused on patients with advanced kidney cancer who had previously undergone unsuccessful therapy. The trial explored the effectiveness of Belzutifan, a first-in-class inhibitor, in treating clear cell renal cell carcinoma (RCC) by targeting the hypoxia-inducible factor. This inhibitor, Belzutifan, works by impeding the dimerization of IF 2A, thereby blocking the downstream oncogenic pathway. The study enrolled over 700 patients and demonstrated positive outcomes. Primary results showed a significant increase in progression-free survival…

Author: Dr Herbert Ho Fung Loong (on-camera comments) – Courtesy of ESMO.org During ESMO 2023, I’ve had the pleasure of presenting our groups data which is the Libretto 431 study which is actually a first line study of the use of supper catching it versus standard chemotherapy plus pembrolizumab in patients with newly diagnosed red fusion positive non small cell lung cancer. So by way of background red fusion accounts for about 2% of all non small cell lung cancers. And previously at least prior to the knowledge of knowing the fact that RET as a driver for most of these…

Author: Dr. Oliver Sartor (on-camera comments) – Courtesy of ESMO.org At ESMO 2023, an opportunity arose to present new data from the [177Lu]Lu-PSMA-617 trial, which focused on metastatic KR-resistant prostate cancer in treatment-naive patients. The study compared two agents from different classes: IS lithium and a secondary hormone (either abiraterone or insulin). Eligibility for the study was determined through PSMA PET scans, which revealed that 92% of patients were qualified. A total of 468 patients were randomized, with the primary endpoint being radiographic progression-free survival (rpfs). The data presented at ESMO showed a significantly positive outcome, with an rpfs Hazard…

Author: Professor Ben Solomon (on-camera comments) – Courtesy of ESMO.org At ESMO 2023, the speaker had the pleasure of presenting the findings from the global phase 3 Alina study. This study marked the first randomized investigation of aninhibitor in patients with entirely resected ALK-positive non-small cell lung cancer. The presentation highlighted the high recurrence rates after surgery in this patient population and emphasized that the advances seen in early-stage immunotherapy didn’t apply here. The standard of care still revolved around Adan Platinum-based chemotherapy. In the Alina study, the effects of two years of LBA2 – ALINA treatment on disease-free survival after…

Author: Dr. Domenica Lorusso (on-camera comments) – Courtesy of ESMO.org During ESMO 2023, the results of the ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial were presented. This trial marked the first evaluation of Pembrolizumab immunotherapy in combination with chemoradiation for locally advanced high-risk cervical cancer since 1999. Historically, the treatment for such patients involved concomitant chemoradiation followed by brachytherapy. However, this trial aimed to demonstrate an improvement in progression-free and overall survival when combining immunotherapy with chemoradiation. A total of 160 patients were enrolled and randomized into two groups: one receiving concomitant chemoradiation followed by brachytherapy with a placebo, and the other receiving the same…

By. Shannon Westin, MDDate. October 27, 2023In the video interview, Shannon Westin, MD, discusses the key findings from the DUO-E Phase III trial, focusing on the combination of IMFINZI® (durvalumab) and LYNPARZA® (olaparib) in advanced or recurrent endometrial cancer and its implications for patient treatment options.Dr. Shannon Westin highlights the significant impact of the DUO-E Phase III trial findings on the management of advanced or recurrent endometrial cancer. She emphasizes that the combination of IMFINZI® and LYNPARZA® showed a remarkable 45% reduction in the risk of disease progression or death when compared to chemotherapy in the overall trial population. This…

By. Brian SlomovitzDate. October 26, 2023 Brian Slomovitz, MD, presented insights into the innovaTV 301 study and its implications for patients dealing with the condition. Within the innovaTV 301 study, crucial findings emerged for cervical cancer patients, showcasing advancements in overall survival, progression-free survival, and objective response rate. These outcomes held significant value for the patients. Specifically, the study highlighted how tisotumab vedotin (TV) extended both the overall and progression-free survival compared to standard chemotherapy. This meant an extended life expectancy and delayed disease progression for patients treated with TV. While the objective response rate was lower than observed in…

By. Neil Gross, MDDate. October 26, 2023 In a discussion detailing the primary outcomes of the Phase 2 trial for Libtayo as a neoadjuvant therapy for Cutaneous Squamous Cell Carcinoma (CSCC), Dr. Neil Gross presented critical aspects related to the study. The trial, incorporating the use of Libtayo, a PD-1 inhibitor developed by Regeneron Pharmaceuticals, Inc., aimed to assess its effectiveness as a neoadjuvant monotherapy in stage II to IV resectable CSCC. This trial marked a significant milestone in oncology and was showcased at the European Society for Medical Oncology (ESMO) Congress 2023 and concurrently published in The Lancet Oncology.…

By: Neal Shore, MD Date: October 25, 2023 In the abstract describing the EMBARK Phase 3 trial, Dr. Neal Shore serves as a key figure in elucidating the trial’s primary objective. The primary aim of this clinical trial is to assess the safety and efficacy of the combination therapy involving enzalutamide and leuprolide in patients with high-risk biochemical recurrence of prostate cancer.The patient group identified as “high-risk for biochemical recurrence” in this trial comprises individuals who have previously undergone primary treatment for prostate cancer and subsequently experienced a rise in prostate-specific antigen (PSA) levels. These patients are at greater risk…

By: Loren Michel, MD Date: October 25, 2023 At the recent ESMO conference, Dr. Loren Michel presented the results of the TROPiCS-03 clinical trial, which investigated the use of sacituzumab govitecan (SG) in advanced head and neck cancer. The primary and key secondary endpoints in this study held significant importance in assessing SG’s effectiveness in patients with advanced HNSCC. The primary endpoint was the objective response rate (ORR), which stood at 16%. The ORR represents the proportion of patients who exhibited a meaningful tumor response to SG, indicating its potential to shrink or stabilize tumors. The key secondary endpoint, the…

By: Thomas Powles, MD Date: October 25, 2023 An exclusive interview occurred with Dr. Thomas Powles, MD, the lead investigator of the EV-302 phase 3 trial, where the discussion revolved around the Enfortumab Vedotin and Pembrolizumab combination and its potential impact on bladder cancer treatment. During the interview, Dr. Powles detailed how the Enfortumab Vedotin-Pembrolizumab combination displayed a 53% reduction in the risk of death in comparison to conventional chemotherapy for bladder cancer patients. The conversation explored the factors contributing to the extended median overall survival of 31.5 months for patients on the combination regimen, a significant improvement over the…

By. Katja Weisel, MD Date: October 25. 2023 In the world of multiple myeloma research, Dr. Katja Weisel, MD, stands at the forefront of groundbreaking clinical trials. Her work on the GMMG-CONCEPT trial, involving Isatuximab combination therapy, has unveiled a pivotal shift in the treatment landscape for high-risk multiple myeloma patients. Achieving sustained minimal residual disease (MRD) negativity is a remarkable feat in the context of this complex blood cancer. MRD negativity implies that there is an exceedingly low level of cancer cells remaining in a patient’s system. In high-risk multiple myeloma, the significance of this achievement cannot be overstated.…

By: Abdulraheem Yacoub MD Date: October 25, 2023 In a prestigious medical conference hall filled with experts in the field of hematological cancers, Abdulraheem Yacoub MD took the stage to address the attentive audience. He commenced his speech with gratitude, saying, “Thank you, Lucia. It’s my pleasure now to invite Abia Kube, who runs what I call an MPN Empire in the middle of the country, and is leading the Limber phase three study in the front line and has also done some great work with the consortium. Thanks, Abe. Good afternoon.” Dr. Yacoub’s appreciation extended further as he continued, acknowledging the…

By: Elizabeth Brem, MD Date: October 06, 2023 Elizabeth Brem, MD, began her talk by addressing some disclosures she had omitted in her previous presentation. She then stressed the importance of intergroup studies, particularly for rare populations like PTCL and HL. She highlighted their unique ability to establish real comparator arms, citing examples from CLL trials. Moving on to specific studies, Dr. Brem emphasized the groundbreaking nature of “eighteen twenty six” in Hodgkin lymphoma, describing it as a study poised to change the standard of care in a way that no other mechanism could achieve. She also discussed the potential…

By: John Mascarenhas, MD Date: October 04, 2023 John Mascarenhas, MD, stands as a distinguished authority in the realm of myelofibrosis treatment. Drawing upon his extensive expertise and experience, Dr. Mascarenhas delivered an enlightening presentation in 2023, shedding light on the drugs Pacritinib and Mamelotnib. During his presentation, he underscored the critical importance of comprehending the distinct properties and profiles of these two JAK inhibitors. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023…

By: Allen Wilbanks Date: October 03, 2023 Julie Vose, MD, a respected expert in the field of lymphoma, began her presentation by acknowledging the challenging nature of mantle cell lymphoma and introduced herself with the following quote: “Thank you very much. So it’s my pleasure to talk about mantle cell lymphoma, another challenging lymphoma. These are my disclosures.” She went on to provide valuable insights into mantle cell lymphoma, emphasizing its prevalence, gender distribution, and the often advanced stage at which patients are diagnosed. Julie stated, “Mantle cell lymphoma, not the most common lymphoma, about sixty nine percent, and patients…

Preventing a Carboplatin Shortage: Strategies to Ensure Cancer Drug Availability in 2023 In an era where advancements in cancer treatment are making great strides, the looming threat of a carboplatin shortage casts a shadow over these achievements. Carboplatin, a critical chemotherapy drug, is essential for treating various forms of cancer. However, recent shortages have disrupted patient care and left healthcare providers scrambling for solutions. What are the consequences of these carboplatin shortages, and how can we address them to ensure that cancer patients receive the life-saving treatments they need? Key Takeaways Carboplatin shortage has caused disruptions in cancer treatment, necessitating…

Harnessing the Power of Dostarlimab to Treat Advanced or Recurrent Endometrial Cancer Endometrial cancer remains a significant challenge for medical oncology. However, recent advances in cancer treatment have brought a new hope for patients with advanced or recurrent endometrial cancer: Dostarlimab. How does this innovative immunotherapy work, and what does it mean for patients with this challenging disease? Read on to discover the breakthroughs of the RUBY trial and the potential impact of Dostarlimab on endometrial cancer treatment. Key Takeaways Dostarlimab (Jemperli) is an innovative immunotherapy approved by the FDA for advanced or recurrent endometrial cancer. The RUBY trial revealed…

GeoVax, a pioneering healthcare company, has developed a groundbreaking product known as GADEPTIN. GADEPTIN is a cutting-edge therapy designed to target and treat the initial indications of advanced head and neck cancer, with the potential to address various solid tumors as well. The mechanism behind this innovative treatment involves the use of an enzyme, the PNP enzyme, which is delivered into the tumor through an established adenovirus vaccine.The treatment process begins by administering the PNP enzyme directly into the targeted tumor. Most tumors are accessible with a needle, making this a precise and localized delivery method. Following the introduction of…

By: Allen WilbanksDate: October 01, 2023 In a conference room filled with medical professionals and researchers, the audience leaned forward, eager to hear the insights of the esteemed Raajit Rampal, MD. As he took the stage, he couldn’t help but make a light-hearted comment about the outdated slides he was presented with. “That’s an outdated slide,” Dr. Rampal remarked with a chuckle. “The Abe is now a full professor.” His comment drew a few laughs from the audience, setting a relaxed tone for the presentation. Dr. Rampal then introduced his collaborator, Doctor Ramal, with warm praise. “And now from the…

By: Allen WilbanksDate: October 02, 2023 In a comprehensive discussion led by the esteemed Swami Lyer, MD, the focus centered on the evolving landscape of therapies for T-cell lymphomas. Dr. Lyer commenced the talk with expressions of gratitude, acknowledging the invaluable contributions of patients participating in clinical studies. The central theme revolved around elucidating the prospects of late and forthcoming treatments in T cell lymphomas, with an emphasis on the pivotal role of transplantation. One of the primary challenges in managing T cell lymphomas is the intricate classification system. Dr. Lyer illustrated the complexity by highlighting the multitude of subtypes…

By: Allen Wilbanks Date: September 29, 2023 In the groundbreaking Phase 3 LUNAR study led by Dr. Ticiana Leal, MD, and her esteemed colleagues, a discovery with the potential to revolutionize the management of metastatic non-small-cell lung cancer (NSCLC) has emerged. This study focused on patients who had experienced disease progression following platinum-based therapy, a group often faced with limited treatment options. The primary objective of the study was to assess the efficacy and safety of TTFields therapy when combined with standard systemic therapy. The results of this study were nothing short of remarkable. Dr. Leal stated, “The randomized, pivotal…

Allen Wilbanks asked Ticiana Leal, MD from the Winship Cancer Institute of Emory University, about her thoughts on the overall impact of TTFields treatment on the lives of patients with lung cancer.Ticiana Leal, MD, shared her perspective, emphasizing the challenges posed by lung cancer and the potential benefits of TTFields treatment for patients, particularly in the second line and beyond. She highlighted that this treatment offers an opportunity to improve survival without introducing additional systemic toxicities or compromising the quality of life.Watch the full interview here

Ticiana Leal, MD, a distinguished oncologist from the Winship Cancer Institute of Emory University, shared her insights during a discussion on the use of Electric Field (ED) therapy for lung cancer, addressing the ongoing challenges and areas for future research. In response to a question posed by Allen Wilbanks, Dr. Leal remarked, “Yeah, I think we’re going to continue to investigate the use of TT fields in non-small cell lung cancer.”With a poised demeanor, Dr. Leal highlighted the importance of comprehending how to integrate TT (Tumor Treating) fields into the existing landscape of systemic therapies. She emphasized this need, not…

By: Allen Wilbanks Date: September 29/2023 At the conference, Pankit expressed gratitude for another great talk, saying, “Thank you, Pankit for another fantastic talk. It’s my honor now to introduce Laura Michaelis, MD, a leader in myeloid malignancies at ASH and SWAG. Thank you, Laura.” Laura Michaelis began her presentation by acknowledging her pleasure to be there and shared two important lessons learned so far – the value of presentation slides and the need for humor. She then delved into essential thrombocythemia, emphasizing the critical importance of accurate diagnosis before treatment. Dr. Michaelis highlighted the significance of thorough diagnostics, especially…

In a recent interview, Peter Fasching, MD, Professor of Women’s Cancer Specialist at the University Hospital in Erlangen, Germany, discussed the findings from the NATALEE trial, focusing on the role of ribociclib in reducing the risk of cancer recurrence in early breast cancer patients while maintaining their quality of life. Dr. Fasching explained that ribociclib is a CDK4/6 inhibitor that can halt the cell cycle and send cells into senescence, making it a promising treatment option for early breast cancer patients.The Natalie trial, which involved over 5,000 patients, revealed that adding ribociclib to standard endocrine treatment resulted in a significant…

AVEO Oncology Fotivda Video Pre-Roll

In a recent discussion on the long-term efficacy and safety of TT field treatment for lung cancer, Allen Wilbanks raised an important question. Ticiana Leal, MD, an esteemed expert from the Winship Cancer Institute of Emory University, provided valuable insights into this topic.Dr. Leal began by highlighting the extensive experience with TT field treatment in patients with glioblastoma. She noted that real-world results for glioblastoma patients have consistently shown efficacy, safety, and improved quality of life, aligning with the landmark trials that led to the approval of TT fields in conjunction with temozolomide.Transitioning to non-small cell lung cancer, Dr. Leal…

In a recent discussion, Ticiana Leal, MD, sheds light on TD Fields treatment for non-small cell lung cancer. This innovative approach offers a unique localized therapy with potential systemic immune effects. However, Dr. Leal emphasizes that it doesn’t replace traditional treatments but complements them. She hints at exciting synergy possibilities when combined with systemic therapies. To learn more, watch the video for a deeper understanding of this groundbreaking approach.Watch the full interview with Ticiana Leal, MD here.

By: Allen Wilbanks Date: September 28/2023 Paolo Strati, MD, an assistant professor at the Anderson Cancer Center in Houston, Texas, delivered a comprehensive presentation on bispecific antibodies and their comparison to CAR T-cell therapy for patients with diffuse large B-cell lymphoma and follicular lymphoma. Dr. Strati emphasized the importance of collaboration in the field and discussed the development of bispecific antibodies, highlighting their journey from single-chain variable fragments to FDA approval. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register –…

By: Allen Wilbanks Date: September 28, 2023 Raajit Rampal MD. PhD, offered a glimpse of what the audience could expect. He mentioned, “We’ll have Rajith talking about Jack one, whether inhibiting it is a good thing or not so much, and what exactly it means in our patients.” He then introduced Steve O, who would delve into Nf Kappa b and present his much-talked-about ACVR research from the last ASH meeting. Rampal introduced the esteemed speakers, acknowledging Steve O from Washu and himself, Raajit Ramal from Stone Kettering. With a playful tone, he acknowledged the potential for missteps, saying, “So…

By: Allen Wilbanks Date: September 27/2023 Swetha Kambhampati, MD, presented at a conference with gratitude to the organizers and Dr. Flowers for the opportunity. She discussed innovative approaches for relapse refractory Hodgkin lymphoma. Dr. Kambhampati outlined her talk, covering BV and PD-1 inhibitors as salvage treatments, novel combinations, emerging immunotherapies, targeted treatments, and the role of stem cell transplants. Standard treatment involves salvage chemotherapy and autologous stem cell transplant, with room for improvement in response rates. BV and PD-1 inhibitors are increasingly used in earlier treatment lines, showing high response rates. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS…

Ticiana Leal, MD, from the Winship Cancer Institute of Emory University, shared her insights during a discussion with Allen Wilbanks regarding the promising potential of TT fields (Tumor Treating Fields) as a treatment modality for cancer patients.When asked about patient subgroups that might benefit more or less from TT field treatment, Dr. Leal responded with a wealth of knowledge and confidence. “I think, from the results of the Lunar trial,” she began, “what we saw was a striking improvement in overall survival in the ICI-treated subgroups.” She went on to elaborate, emphasizing the significance of combining immune checkpoint inhibitors (ICI)…

In this informative video, viewers will gain valuable insights into the groundbreaking research discussed by medical experts Ticiana Leal, MD, from the Winship Cancer Institute of Emory University, and Allen Wilbanks. The discussion revolves around the implications of recent findings for clinical practice in the field of oncology.Dr. Ticiana Leal begins by highlighting the significance of the study, emphasizing its novelty in demonstrating an improvement in overall survival for patients who have previously undergone platinum-based chemotherapy and are now being treated with immune checkpoint inhibitors (ICIs) as a first-line therapy. She underscores the importance of these findings as a potential…

By: Allen Wilbanks Date: September 27, 2023 Stephen Oh, MD PhD, took the podium to present his research in a room filled with anticipation. He began with a casual tone, saying, “I just wanna level set for the audience here. I’m gonna try to keep this science-y. I can’t promise you I won’t say something stupid.” He humorously added, “And, since I have two talks, if you wanna do a gladiator-style thumbs up or thumbs down after the first one, as to whether I’m allowed to proceed, I’m okay with that.” REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS…

By: Allen Wilbanks Date: September 27,2023 In a recent presentation, Elizabeth Brem, MD shared her perspective on the utilization of minimal residual disease (MRD) technology in clinical trials and its potential to transform patient care. She emphasized the various applications of MRD, including its role in guiding time-limited therapies to reduce toxicity, intensifying or extending therapy based on patient needs, and altering therapy strategies, especially in conditions like CLL. Dr. Brem noted that solid tumor colleagues have been more advanced in utilizing MRD technology clinically, while the lymphoma community is catching up to leverage it for patient care improvements. REGISTER NOW…

In a groundbreaking lunar trial, Ticiana Leal, MD, a distinguished expert from the Winship Cancer Institute of Emory University, spearheaded a Phase three study that promised to reshape the landscape of cancer treatment. This global, randomized study aimed to scrutinize the safety and efficacy of tumor treating fields (TT fields) therapy in conjunction with standard-of-care therapies. The subjects of this trial were patients grappling with advanced non-small cell lung cancer, a cohort that had experienced progression after undergoing platinum-based chemotherapy.In a nutshell, the primary objective was to fathom the impact of TT fields therapy, either combined with an immune checkpoint…

Ticiana Leal, MD, is at the forefront of an intriguing and evolving discussion centered on the mechanism underlying tumor treating fields (TT fields). These fields are a topic of great interest in the field of oncology, and Dr. Leal’s expertise shines through as she delves into the question at hand: how do tumor-treating fields actually work?TT fields, a novel approach in cancer therapy, harness the power of electric fields to interact with electrically charged components within the human body, specifically targeting dividing cancer cells. Their precise mode of action revolves around disrupting the crucial process of mitosis, where cells divide…

By: Allen Wilbanks Date: September 27, 2023 Myeloproliferative neoplasms (MPNs) are a group of blood disorders characterized by the overproduction of blood cells in the bone marrow. Andrew Kuykendall, MD, a well-known hematopathologist and engaging speaker, recently addressed the topic of “WHO versus ICC and the Implications within MPNs” in a presentation. Despite not being directly involved in either classification system, Dr. Kuykendall offered a unique third-party perspective on the matter, comparing and contrasting the two systems and their implications for MPNs. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU -…

By: Allen Wilbanks Date: September 27 /2023 John Leonard, MD, a prominent figure in the field of oncology, delivered a thought-provoking presentation at a medical conference. His words were a reflection of his deep commitment to improving patient outcomes and quality of life. In his address, he discussed various aspects of treating lymphomas, particularly follicular lymphoma and diffuse large B cell lymphoma, emphasizing the importance of considering these factors when making treatment decisions. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open…

By: Allen Wilbanks Date: 09/27/2023 William Shomali, MD, is a respected expert in systemic mastocytosis, known for his collaborative work with Jason Gottlieb at Stanford University. In a recent presentation, he shared valuable insights on this complex condition. Dr. Shomali began by expressing gratitude for the invitation and acknowledged MD Education for arranging the event. He then delved into systemic mastocytosis, emphasizing its challenging diagnosis due to the loss of granules in fixed tissue samples. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU -…

By: Allen Wilbanks Date: 09/27/2023 REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Sandeep Dave, MD, discussed the challenges of classifying and treating various blood cancers, including diffuse large cell lymphoma, follicular lymphoma, mantle cell lymphoma, and peripheral T cell lymphomas. He emphasized the importance of genomic profiling in understanding the heterogeneity of these diseases. For diffuse large cell lymphoma, Dr. Dave highlighted the complexity of subgrouping patients based on genetic alterations,…

By: Pankit Vachhani, MD Date: 09/22/2023 REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The audience was eagerly awaiting the insights of Dr. Pankit Vachhani, a long-time friend and mentee. As the presentation commenced on “Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes,” attendees were in for a comprehensive exploration of the topic. Despite his usual penchant for occupying the back seats, Dr. Vachhani humorously admitted, “Usually, I’m the guy who sits in…

By: Christopher Flowers, MD Date: 09/22/2023 Dr. Christopher Flowers of MD Anderson Cancer Center expressed his gratitude to Sandeep for his excellent talk, acknowledging it as a perfect precursor to his own discussion on integrating tools into clinical practice and trials. Dr. Flowers shared his relevant disclosures, mainly involving his role as a consultant in lymphoma therapy development and his work in the Division of Cancer Medicine. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US…

In a conversation hosted by Allen Wilbanks, Solange Peters, MD, PhD, a full professor and chair of medical oncology specializing in thoracic malignancies at the University Hospital of Lausanne in Switzerland, discussed the remarkable findings from the CheckMate 227 trial, particularly the six-year outcomes of Nivolumab and Ipilimumab as first-line treatment for metastatic non-small cell lung cancer.Dr. Peters emphasized that Nivolumab and Ipilimumab, being chemotherapy-free, offer an intriguing approach based solely on immune responses. Another key aspect is that the treatment stops at two years, allowing researchers to evaluate the long-term effects of promoting an immune response.Regarding the use of…

an AML-ALL US Focus Meeting 2023 video

Jack West, MD is an associate professor in medical oncology specializing in thoracic oncology at the City of Hope Comprehensive Cancer Center in the Los Angeles area. Recently, he discussed the highly anticipated FLAURA2 trial during the World Conference on Lung Cancer in Singapore. In his words, “Hi, I’m Jack West. I’d like to talk about the FLAURA2 trial, which was among the most anticipated presentations at the just completed World Conference on Lung Cancer in Singapore.”The FLAURA2 trial aimed to compare the efficacy of Osimertinib as a single agent versus Osimertinib combined with chemotherapy as a first-line treatment for…

In a discussion with Allen Wilbanks from Oncology Tube, Brandon McNaughton, CEO & Founder of Akadeum Life Sciences, shed light on the innovative Akadeum’s human T cell activation and expansion kit and its impact on cell therapy. McNaughton explained the advantages of their microbubble-based technology compared to traditional methods, highlighting its gentleness, scalability, and compatibility with various cell culture systems.He stated, “What’s different about what we do, which is using tiny floating particles, we call them micro bubbles to essentially reach into a sample, essentially a blood bag that was derived from a phoresis or Luca pack. We use microbubbles…

In the pivotal phase 3 LUNAR study, Ticiana Leal, MD, and her colleagues made a groundbreaking discovery that could revolutionize the treatment of metastatic non-small-cell lung cancer (NSCLC) in patients who have experienced disease progression following platinum-based therapy. The study, which aimed to evaluate the efficacy and safety of TTFields therapy in combination with standard systemic therapy, yielded remarkable results.Dr. Leal stated, “The randomized, pivotal phase 3 LUNAR study provides level 1 evidence that TTFields therapy, an innovative, locoregional treatment method, applied concomitantly with standard systemic therapy significantly improves overall survival in patients with metastatic non-small-cell lung cancer following progression…

OneOncology, a rapidly expanding national platform for independent medical practices, proudly announces the completion of 25 distinctive oncology and hematology pathways. These pathways are now integrated into the platform’s clinical decision support tool, a testament to OneOncology’s dedication to precision and excellence. Lisa Sowinski-Raff PharmD, serving as Vice President of Pharmacy Services, plays a pivotal role in this achievement.OneOncology adopts a physician-driven approach to pathway development, led by Medical Director Edward Arrowsmith, MD. Experts in gastrointestinal, genitourinary, breast, lung, and hematology, along with disease subject matter experts in gynecology and head and neck specialties, meticulously craft and continuously update these…

Timothy Looney, PhD – Senior Director, Immunology and Bioinformatics at Singular Genomics By: Timothy Looney, PhD Date: 9/12/2023 The topic at hand revolves around “Immune-Related Adverse Events (IRAEs)” in the context of cancer treatment using “Immune Checkpoint Inhibitors (ICIs).” Timothy Looney, a prominent researcher with a PhD, discusses the significance of IRAEs in cancer immunotherapy. IRAEs are adverse events that occur when therapeutic agents like ICIs activate T cells, causing them to mistakenly target healthy tissues, leading to damage or destruction. These events, which can range from mild to life-threatening, are a major concern in cancer immunotherapy due to the…

The interview with Jill O’Donnell-Tormey, PhD, delves into the vital topic of cancer immunotherapy and research, emphasizing the transformative potential of harnessing the human immune system to combat various forms of cancer. Throughout the conversation, O’Donnell-Tormey provides valuable insights and perspectives on key areas of focus within the field. Here are some direct quotes from her on these topics:On the mission of the Cancer Research Institute (CRI):”We are a non-profit organization that’s been around for 70 years with the singular view that your immune system could be harnessed as a way to treat, control, and potentially cure all cancers.”On the…

In the interview, Susan Pandya, MD, Vice President of Clinical Development at Servier Pharmaceuticals, discusses the pivotal FDA acceptance and priority review for TIBSOVO in the treatment of IDH1-mutated relapsed or refractory myelodysplastic syndromes (MDS). The acceptance marks a significant milestone in advancing targeted therapies for patients facing limited options in this challenging disease context.TIBSOVO’s clinical data submission showcased remarkable results, with complete remissions achieved in approximately 40% of patients and an overall response rate of 83.3% among those with relapsed or refractory IDH1-mutated MDS. These outcomes far exceed existing treatment options, underscoring TIBSOVO’s potential as a transformative therapy for…

Marwan Fakih, MD – City of Hope – FDA Approval of LONSURF in combination with Bevacizumab The FDA approval of Lonsurf plus Bevacizumab represents a significant breakthrough in the treatment of metastatic colorectal cancer. This combination therapy offers new hope for patients who have previously exhausted their treatment options, providing substantial improvements in both overall survival and progression-free survival. The clinical trial results from the Sunlight trial have solidified Lonsurf plus Bevacizumab as the standard third-line treatment for metastatic colorectal cancer, with potential implications for future research and control arms in clinical trials. Physicians are encouraged to consider this combination…

Joshua Brody, MD – Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount SinaiHess Center for Science and Medicine – Pattern recognition receptor agonists in pathogen vaccines mediate antitumor T-cell cross-priming What is the role of primed CD8 T-cells in cancer immunotherapies, and how does their recognition of tumor antigens presented on MHC-I contribute to the antitumor response?What are the critical factors in loading dendritic cells (DC) with tumor antigens, and how can we optimize this process to enhance antitumor T-cell responses?Can you explain the advantages and limitations of using neoantigen vaccines based on individualized tumor exome and RNA…

In the interview with Allen Wilbanks of OncologyTube, Peter Langmuir, the Vice President of Oncology Drug Development at Incyte, discussed the Agave 201 trial and its outcomes. Mr. Langmuir explained, “The Agave 201 trial was a clinical trial in patients with chronic GVHD, looking at the drug axatilimab, a monoclonal antibody against the CSF1 receptor. That was originally developed by our partners at syntax. And this trial was initiated by them to do two things. First of all, one was to try to identify the most appropriate dose of axatilimab to use in these patients based on both safety and…

The recent approval by the Food and Drug Administration (FDA) of mirvetuximab soravtansine-gynx (Elahere) marks a significant advancement in the treatment landscape for adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. This article aims to provide oncologists with a comprehensive overview of the efficacy, safety profile, and prescribing considerations associated with this novel therapeutic agent. Efficacy Evaluation: Study 0416 Mirvetuximab soravtansine-gynx’s (Elahere) approval was based on data from Study 0416 (MIRASOL), a pivotal multicenter trial involving 453 patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Patients enrolled in the study had…

Mark Schoenberg, MD- UrologyGenitourinary (GU) CancerBladder Cancer-The Montefiore Medical Center and The Albert Einstein College of Medicine at UroGen Pharma What is UGN-102, and what is its potential role as the first non-surgical therapy for LG-IR-NMIBC? Could you explain the primary endpoints achieved in both the ATLAS and ENVISION clinical trials for UGN-102? In the ATLAS trial, UGN-102 showed a 55% reduction in the risk of recurrence, progression, or death compared to TURBT. How significant is this finding for patients with LG-IR-NMIBC? What was the complete response rate at three months observed in the ENVISION trial, and how does it…

Elizabeth Brem , MD discusses the design and outcomes of the study referred to as 1826. The study aimed to enhance outcomes and address toxicities in Hodgkin lymphoma treatment. Nivolumab’s potential benefits in comparison to brentuximab within the AVD backbone were explored. Additionally, Brem highlights the collaborative nature of the study, involving adult and pediatric cooperative groups, Canadian cooperative groups, and the children’s oncology group. This collaboration played a pivotal role in the trial’s success, enabling rapid accrual and earlier achievement of primary endpoints.Elizabeth Brem emphasizes that the study achieved its primary objective by improving progression-free survival in patients with…

Shirin Attarian, MD addresses the escalating incidence of head and neck cancer and highlights that most cases, particularly oropharyngeal cancers, are driven by HPV virus infection. She discusses HPV vaccination recommendations, suggesting that individuals between 11 and 26 years old should be vaccinated, potentially starting from age 9. Vaccination for those aged 27-45 is possible after physician consultation but might be less effective due to prior exposure. Beyond 45, there are no current vaccination recommendations. Attarian explains that despite younger generations getting vaccinated, the incidence of head and neck cancer is anticipated to rise in older individuals who aren’t vaccinated.…

Nataliya Mar, MD Clinical Associate Professor in the Division of Hematology/Oncology at the University of California Irvine, provides GU ASCO Updates [2023]. What were the VESPER trial results? What were the CONTACT-03 trial results? In the case of the 68-year-old man with metastatic prostate cancer, who had initial response but then developed PSA rise, what are the key considerations when selecting treatment options for patients with somatic and germline DDR alterations? How do PARP inhibitors fit into the treatment landscape? What were the TALAPRO-2 trial results?

Rafael G. Amado, M.D., President, Head of Global Oncology Research and Development, leading and overseeing the company’s global oncology research and development activities. In a pivotal Phase 3 randomized clinical trial, niraparib maintenance therapy has demonstrated remarkable efficacy for patients recently diagnosed with advanced ovarian cancer following initial platinum-based chemotherapy. This trial, involving 384 participants, unveiled the significant potential of niraparib in extending progression-free survival rates by a substantial 55% when compared to a placebo control group. Notably, the treatment’s effectiveness was observed across diverse patient subsets, regardless of their biomarker status or the presence of residual disease. These findings…

Pre-Roll Example

Advertising on OncologyTube For A Limited Time No Contracts! Pay As You Go! Book Now! or Contact Us for More Info or Call 1 (951) 944-2173 (Discounts available for 3, 6, and 12 month contracts) Why OncologyTube? $120 CPM the lowest in the industry (for a limited time only) 90% of our unique content is created by MD oncologists for oncologist. We work with the biggest pharmaceutical, research hospitals, and universities in the world. The most well-known oncology KOLs and researchers contribute to our platform. 10,000+ NPI-verified oncologists subscribed to our monthly eNewsletter. Thousands more worldwide. 20,500+ Social Media followers mostly…

Sanam Loghavi is Assistant Professor, Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX The talk covered the emerging field of menin inhibition in AML, shedding light on its potential as a novel therapeutic strategy. The enthusiasm around this development was palpable in the presentation, reflecting the speaker’s excitement for the advancements in understanding and treating AML. Additionally, the evolving classification of AML was discussed, showcasing the dynamic nature of the field and the constant discovery of new entities within it. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US…

Yasmin Abaza, MD Assistant Professor, Medicine (Hematology and Oncology) In a captivating interview, Yasmin Abaza, MD, an esteemed Assistant Professor of Medicine at Northwestern University, delved into her research focus on Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). Offering a comprehensive overview of immune cell therapies for these conditions, Dr. Abaza touched upon the historical struggles encountered in achieving successful outcomes. She candidly highlighted the limited success observed thus far while shedding light on the promising agents currently undergoing clinical trials. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU -…

Jessica Altman, MD – Professor, Medicine, Hematology Oncology Division; Feinberg School of Medicine Jessica Altman, MD, a dedicated professional at Northwestern University in Chicago, recently participated in her first conference, which proved to be a remarkable experience. At this event, she engaged in a thought-provoking debate with Dr. Dauver, focusing on the treatment of acute myeloid leukemia (AML) in adults with newly diagnosed cases. The debate centered on the comparison between triplet-based therapy and sequential therapy. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU -…

Elias Jabbour, MD – Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX Elias Jabbour, MD a dedicated professional at MD Anderson in Houston, Texas, recently presented groundbreaking insights at a conference. Formerly dire disease survival rates have been revolutionized, with ten-year survival now at an impressive ninety percent within four to five years. This transformation represents a new standard of care and a remarkable advancement for patients. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open…

The discussion focuses on the changing landscape of treatment for mutated acute myeloid leukemia (AML). The speaker emphasizes the significance of mutation profiles in AML patients, which can have prognostic or therapeutic implications. Poultry inhibitors are believed to have a lasting impact, with many candidates already approved or under investigation. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The session’s agenda involves a brief introduction followed by experts discussing various aspects of…

Bijal Shah, MD, MS- Hematology/Oncology- Moffitt Cancer Center Bijal Shah MD, MS, emphasizes the positive outcomes of CAR T cell therapy for patients with relapsed refractory conditions, particularly those who have experienced multiple relapses and high tumor burdens. They highlight the success achieved with CAR T therapy, especially after treatment with Blinatumomab (Blina) and Inotuzumab Ozogamicin (I know). REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Bijal Shah MD, MS,…

Charles G. Mullighan, MBBS (Hons), MSc, MD-Member, St. Jude Faculty-Deputy Director, Comprehensive Cancer Center-St. Jude Children’s Research Hospital Charles Mullighan, MD, delves into the genomic classification of Acute Lymphoblastic Leukemia (ALL) and its diagnostic approaches. He covers three main areas: B-cell ALL (BOL), implications for risk stratification and diagnosis, and insights into the classification of T-cell ALL (TOL). REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com After a decade of genomic research,…

Sayeh Lavasani, MD of UCI Health gives an Update in Breast Cancer at MOASC’s Spotlight on Oncology NATALEE’s study focused on comparing adjuvant ribocyclib plus a non-steroidal AI versus an AI alone in high-risk, early-stage, hormone receptor-positive breast cancer patients. The ribocyclib was administered at a lower dose of 400 milligrams daily for three weeks on and one week off, over three years. This study showed improvements in invasive disease-free survival, as well as trends towards enhanced overall survival in a three-year follow-up. These findings suggest an additional treatment option to reduce the risk of recurrence in earlier-stage hormone-positive breast…

Regina Myers, MD, MSCE, is an instructor in the Cancer Center at Children’s Hospital of Philadelphia. Regina Myers, MD expresses gratitude for the audience’s presence and thanks the event organizers for the invitation. They introduce themselves as a pediatric oncologist speaking at an adult conference, focusing on pediatric AAA (acute lymphoblastic leukemia) and 4-1BB CAR T cell therapies. They mention the high complete response (CR) rates of up to 97% achieved with CAR19 (CAR targeting CD19), but also note the significant challenge of disease relapse after CAR19 treatment, especially in pediatric and adult patients. They attribute relapse to two main…

Shira N. Dinner, MD- Robert H Lurie Cancer Center Shira N. Dinner, MD discussed several studies focused on the treatment of acute lymphoblastic leukemia (ALL) in older adults, particularly those aged 55 and above. The presentation highlighted the challenges and outcomes associated with different treatment approaches. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTSAML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Shira N. Dinner, MDfirst emphasized the historical poor outcomes for older adults with ALL, with survival rates being notably lower compared to…

Hagop Kantarjian, MD is professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center Hagop Kantarjian, MD shared exciting updates and progress in the treatment landscape. Notably, some of the predictions made back in 2010 are now proving to be successful. Initiatives like the development of the blinatumomab and inotuzumab therapies started in 2008 and by 2010, it was clear that using them as standalone treatments would not be effective, prompting a shift towards combination therapies. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTSAML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/AML-ALL EU -…

When your patient is diagnosed with a blood cancer such as chronic lymphocytic leukemia (CLL), it’s important to remember that in addition to their physical health, their mental health is a critical part of their overall well-being.1 From initial diagnosis through remission, it’s essential to ensure patients are equipped with tools and resources to help them manage the various emotions that come with a diagnosis and know how to seek professional help when needed. Many patients feel a certain stigma around mental health, so it’s important to initiate the conversation. Helping patients figure out how to create an action plan…

Nitin Jain, M.D., is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA. Nitin Jain, MD, discussed relapsed/refractory T-cell acute lymphoblastic leukemia (TLL) and the need for new therapies due to the ineffectiveness of current treatments. They highlighted studies that assessed outcomes in relapsed TLL, demonstrating a median survival of four to six months, indicating the significant unmet medical need. Nitin Jain, MD, also mentioned the criteria for defining early T-cell precursor leukemia (ETPL) based on gene expression and flow cytometry markers. They discussed different approaches for treating…

Bijal Shah, MD, MS- Hematology/Oncology- Moffitt Cancer Center Bijal Shah MD, MS, emphasizes the positive outcomes of CAR T cell therapy for patients with relapsed refractory conditions, particularly those who have experienced multiple relapses and high tumor burdens. They highlight the success achieved with CAR T therapy, especially after treatment with Blinatumomab (Blina) and Inotuzumab Ozogamicin (I know). REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Bijal Shah MD, MS,…

Marina Konopleva, MD, PhD – University of Texas MD Anderson Cancer Center and Albert Einstein College of Medicine Jack and Pearl Resnick Campus The discussion revolved around patients with B-cell acute lymphoblastic leukemia (ALL) that had a gene expression signature similar to Philadelphia chromosome-positive ALL (Ph+ ALL) but lacked the characteristic genetic abnormalities. This subgroup, referred to as “PH-like ALL,” comprised around 20-30% of ALL cases, with a higher prevalence in pediatric patients. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ ML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU -…

Marlise Luskin,MD, MSCE- Medical Oncology- Dana-Farber/Mass General Brigham Hematology/Oncology Fellowship Program and education director for the adult leukemia program. The presentation focused on the use of the drug venetoclax (and its related drugs) in the treatment of acute lymphoblastic leukemia (ALL), particularly relapse refractory ALL. The speaker outlined the significant progress that has been made in the treatment of this disease, including various therapies like blinatumomab, iituzumab, and CAR T cell therapy, which have shown improvements but still leave certain subsets of patients with unmet needs. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content…

Elias Jabbour, MD- Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX Elias Jabbour, MD discussed the potential treatment options for patients facing relapsed leukemia during a medical presentation. He emphasized the importance of considering complementary strategies rather than competing ones. Dr. Jabbour advocated starting with bispecific and immunotherapy approaches before utilizing CAR T-cell therapy due to their positive impact on survival. He referred to the dire prognosis of relapsed patients, comparing it to a death sentence, and highlighted the challenges associated with traditional treatments like transplantation. REGISTER NOW TO JOIN US AT THESE UPCOMING…

IMpower010 & Atezolizumab: The trial has cemented the significance of atezolizumab in the potential treatment options for lung cancer, especially as an adjuvant in non-small cell lung cancer (NSCLC). Debate & Discourse: While promising, the broadened approval and usage of atezolizumab have sparked meaningful debate regarding its universal applicability and effectiveness. Unbiased Presentation: The oncological community must remain vigilant, ensuring that data and results are presented without bias, offering patients and practitioners clear insights into potential treatment modalities. In the vast realm of oncology, lung cancer remains a predominant concern and focus of rigorous scientific research. At the forefront of…

Ryan D. Cassaday,MD- Physician-Fred Hutch Ryan Cassaday, MD emphasizes the importance of the topic at hand and humorously compares the debate between inotuzumab and blinatumumab to choosing between seat belts and airbags, highlighting his belief that both treatments have significant roles to play. Dr. Cassaday focuses on presenting data supporting inotuzumab, specifically in the context of older adults with pH-negative B cell acute lymphoblastic leukemia (ALL). He discusses studies from MD Anderson and the German Cooperative Group that showcase the effectiveness of inotuzumab in inducing morphologic remission and achieving favorable survival curves, despite challenges such as toxicity. REGISTER NOW TO…

Anjali Advani, MD- Hematology and Medical Oncology- Cleveland Clinic Anjali Advani, MD, begins her talk by expressing gratitude for the invitation to speak. She proceeds to discuss the integration of blinatumomab into upfront therapy for acute lymphoblastic leukemia (ALL). Dr. Advani explains that blinatumomab, a bispecific antibody engaging CD3 and CD19, effectively induces T-cell proliferation and apoptosis of leukemia cells. She emphasizes blinatumomab’s advantages, including its lack of attached chemotherapy, reduced risk of complications, and potential immune effects. Dr. Advani discusses ongoing efforts to refine blinatumomab’s administration and dosage for optimal patient outcomes. REGISTER NOW TO JOIN US AT THESE…

Aaron Logan, MD, PhD- Associate Professor of Clinical Medicine, Division of Hematology/Oncology, UCSF Aaron Logan, MD PhD, conveyed his gratitude to the event organizers and acknowledged the valuable input of different perspectives at the meeting. He highlighted the critical role of assessing minimal residual disease (MRD) in leukemia treatment strategies. Drawing on data from various studies, Dr. Logan underscored how MRD presence or absence can accurately predict survival outcomes in patients undergoing therapy for leukemia. However, he also acknowledged the limitations of MRD assessments, as they don’t always perfectly predict relapse or remission. He discussed the importance of precise MRD…

Jalen Patel, MD – City of Hopeaugust 21, 2023Drawing from data provided by ASCO and Friends of Cancer Research, the study endeavors to characterize the eligibility criteria employed in advanced prostate cancer investigations. The primary objective centers on ensuring that the clinical trial parameters accurately reflect the broader population.The classification involves three distinct categories: exclusion, conditional inclusion, and instances where criteria were not reported. Upon scrutinizing the criteria of interest, the analysis reveals a predominant tendency among trials to exclude individuals with brain metastases, HIV, hepatitis B and C, as well as concurrent malignancies. The subsequent breakdown of four figures…

Akasha Dukkipati, MD at City of Hope August 21, 2023 Akasha Dukkipati, MD at City of Hope, conducted an analysis of urothelial cancer studies spanning a decade, from 2012 to 2022. The aim was to scrutinize eligibility criteria due to concerns raised by a collaborative statement from ASCO and Friends of Cancer Research. The joint statement underscored the underrepresentation of certain clinical attributes resulting from overly stringent eligibility standards in clinical trials. The physician’s team specifically focused on advanced urothelial cancer studies, examining four primary exclusion factors: concurrent malignancies, brain metastases, hepatitis B and C infections, and HIV. Their findings…

Mark Litzow, MD- Hematologist, Oncologist, Palliative Care Specialist- Mayo Clinic In a presentation delivered by Mark Litzow, MD, the speaker expresses gratitude for the invitation and acknowledges the organizers. The speaker humorously remarks that they are unsure who needs transplants nowadays. They express their intention to address the question of who needs transplantation in the first remission (CR1) and highlight the importance of relapse and its relation to transplant outcomes. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register –…

Branko Cuglievan, MD- Assistant Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX – Section Chief, Leukemia/Lymphoma, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX Branko Cuglievan, MD, expresses gratitude for being invited to an adult conference to discuss pediatric data and challenges. He addresses the differences in age distribution between acute myeloid leukemia (AML) and pediatric leukemias. Dr. Cuglievan emphasizes the lower incidence of pediatric AML cases and the struggle to enroll sufficient patients for studies due to the dispersed…

Charles G. Mullighan, MBBS (Hons), MSc, MD-Member, St. Jude Faculty-Deputy Director, Comprehensive Cancer Center-St. Jude Children’s Research Hospital Charles Mullighan, MD, expresses gratitude for the invitation to speak at the meeting and discusses the genomic classification of leukemia, particularly focusing on B-cell acute lymphoblastic leukemia (B-ALL) and T-cell acute lymphoblastic leukemia (T-ALL). He covers three main areas: B-ALL genomic classification, its implications for diagnosis and risk assessment, and recent unpublished data on T-ALL classification. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open…

Elias Jabbour, MD- Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX The talk, delivered by Elias Jabbour, MD, centers around the treatment paradigm for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), proposing a shift from traditional chemotherapy to tyrosine kinase inhibitors (TKIs) and immunotherapy. Dr. Jabbour discusses the historical use of allogeneic stem cell transplantation and its limitations. The presentation delves into data from MD Anderson and other studies, emphasizing the challenge of achieving high survival rates. The concept of complete molecular remission (CMR) is underscored, with an emphasis on early molecular response deepening.…

Wendy Stock, MD – Anjuli Seth Nayak Professor of Medicine- The University of Chicago Medicine In this presentation, Wendy Stock, MD, addresses optimizing outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Dr. Stock expresses gratitude for the opportunity and highlights the importance of such meetings, drawing from her own experience when starting her career. She discusses the positive changes in patient outcomes, particularly emphasizing minimal residual disease (MRD) eradication as a key goal. The importance of blending new therapies with older approaches and using less aggressive treatment for older patients and AYAs is mentioned. Dr. Stock…

Marina Konopleva, M.D., Ph.D.- Professor, Department of Oncology (Medical Oncology) Professor, Department of Molecular Pharmacology- Albert Einstein College of Medicine In this presentation by Marina Konopleva, MD, she covers the resistance mechanisms and potential combination strategies related to venetoclax, an AML (acute myeloid leukemia) treatment. Despite overlapping slides, she delves into the topic, shedding light on resistance challenges. Konopleva elaborates on the mechanism of action, targeting BCL-2, and its interaction with mitochondrial proteins. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/…

Tapan Kadia, MD- Professor, Department of Leukemia, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX In this presentation Tapan Kadia, MD discusses the challenge of high relapse rates despite achieving complete remissions with newer therapies. Historical attempts at maintenance therapy are reviewed, with improvements seen in relapse-free survival but not overall survival. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Dr. Kadia highlights the success of oral hypomethylating…

Hetty Carraway, MD- Hematology and Medical Oncology- Cleveland Clinic Hetty Carraway, MD, delivers a comprehensive discussion on immune-based and novel strategies to enhance outcomes for patients with myelodysplastic syndromes (MDS). The focus lies on unraveling the intricate relationship between the immune system and MDS pathogenesis, exploring immune interventions like immune checkpoint inhibitors (ICIs), and addressing challenges related to immune manipulation, mutational profiles, and the microenvironment. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus…

Andrew Artz MD- Hematologist-Oncologist- City Of Hope Andrew Artz, MD, expresses gratitude to the organizers and prior presenters, acknowledging the topic’s extensive coverage. Playfully, he considers sharing random pictures or dinner plans but proceeds to discuss his presentation’s content. He highlights the increasing use of allogeneic transplants, especially for older patients and those in first remission, attributing this rise to novel therapies. Dr. Artz emphasizes the challenge of relapse and the need to balance it against transplant-related toxicities. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open…

Yasmin Abaza, MD Assistant Professor, Medicine (Hematology and Oncology) Yasmin Abaza, MD discusses advancements and challenges in the treatment of Acute Myeloid Leukemia (AML) using immunotherapies. Over the past five decades, outcomes for AML patients have improved, but long-term survival rates remain low, highlighting the need for new treatment options. Allogeneic stem cell transplantation is a potent immunotherapy for AML, particularly in patients with intermediate or adverse risk disease. The transplantation’s effectiveness lies in the donor T cell’s ability to target and destroy leukemia cells through interactions with AML cells’ molecular markers. Despite its benefits, this approach is associated with graft-versus-host…

Dr. Ghassan Abu Alfa, MD with Memorial Sloan Kettering Cancer Center in New York, provides an update on the key findings of the Himalaya clinical trial. The trial, a phase 3 study, investigated the combination of darvalumab and tremelumab for patients with intractable hepatocellular carcinoma. The study involved a phase 3 clinical trial, comparing the combination therapy to sorafenib, the prevailing standard care at that time and widely used globally. The primary focus was on enhancing survival outcomes with the combination of Dervalumab and Tremelumab versus Sorafenib. Notably, the median overall survival was approximately 16.5 months for the combination therapy…

Dr. Jack West,MD an associate professor in medical oncology at City of Hope Comprehensive Cancer Center in Los Angeles, discussed a recent publication in the Annals of Oncology regarding the IMpower010 trial. The trial focused on the adjuvant use of atezolizumab and was initially presented by Dr. Heather Wakely and colleagues at ASCO 2021. The trial showed a statistically significant improvement in disease-free survival for patients with stage 2 to 3a resected non-small cell lung cancer and PD-L1 of 1% or higher who received adjuvant atezolizumab compared to placebo. While the trial demonstrated benefits in disease-free survival, further analysis reveals…

Naval Daver MD is an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center. Naval Daver, MD expresses uncertainty and discusses the need for personalized treatment strategies. He mentions starting with a metaphor about eggs and ice cream preferences. They highlight the lack of data on triple therapy and the importance of considering individual differences. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The talk shifts to triple…

Brian Andrew Jonas, M.D., Ph.D.- Hematology and Oncology – Hematology and Oncology – UC Davis Comprehensive Cancer Center The presentation discusses the management and treatment strategies for patients with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) receiving hypomethylating agents (HMA) in combination with venetoclax. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Brian Andrew Jonas, M.D., Ph.D. discusses various aspects of this treatment approach, including dosing regimens, response…

Jessica Altman, MD – Professor, Medicine, Hematology Oncology Division; Feinberg School of Medicine The presentation discusses various aspects of treatment strategies for newly diagnosed acute myeloid leukemia (AML), focusing on optimizing therapy approaches and providing practical insights for healthcare professionals. It delves into considerations for patients who are not suitable for intensive chemotherapy, explores the use of different approved or accessible agents, and emphasizes the importance of achieving transfusion independence and improved quality of life for AML patients. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open -…

In the dynamic world of oncology, chemotherapy stands as a beacon of hope for many battling the formidable challenge of cancer. When diagnosed with cancer, patients are presented with a spectrum of treatment modalities, and one of the most crucial decisions revolves around when and how to administer chemotherapy. Amidst the plethora of choices, one term has steadily gained prominence: neoadjuvant chemotherapy. But what is neoadjuvant chemotherapy? And how does it distinguish itself from other treatment strategies? What is Neoadjuvant Chemotherapy? Stepping into the world of oncology, terms and treatments can often feel overwhelming. Amidst the myriad of terminologies, neoadjuvant…

Courtney DiNardo, MD- Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Emerging as a beacon of hope in the realm of acute myeloid leukemia (AML) treatment, a new frontier is being forged through the synergistic power of innovative drug combinations. By intertwining the potency of IDH inhibitors like ivosidenib and enasidenib with hypomethylating agents and the precision of venetoclax, a novel therapeutic approach is taking center stage. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open…

Eytan M. Stein, MD – Hematologist-Oncologist – Memorial Sloan Kettering Cancer Center Discover the cutting-edge landscape of acute myeloid leukemia (AML) treatment with a focus on Revumenib and Ziftomenib, two promising menin inhibitors. Delving into the realm of AML therapy, this discussion navigates through the potential roles of Revumenib and Ziftomenib in treating relapsed and refractory cases, particularly among patients with KMT2A rearrangements and NPM1 mutations. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US…

Presented By: Brian Warnecke, DO – UC-Irvine Hematology Oncology Fellow, PGY-5 Date: August 12, 2023The presentation titled “Multi-omic Characterization of RCC1 Expression and its Association with Molecular Alterations, Immune Phenotypes, and Cancer Outcomes,” conducted by Brian Warnecke, D.O., a UC-Irvine Hematology Oncology Fellow in his PGY-5, unveils a comprehensive investigation into the multifaceted role of Regulator of Chromosome Condensation 1 (RCC1) in cancer development and progression. Collaboratively led by principal investigators Dr. Mohammed Al Hallak (Karmanos), Dr. Asfar Azmi (Karmanos), and Dr. Misako Nagasaka (UC Irvine), this research endeavor delves into the intricate interplay between RCC1 expression, molecular alterations, immune…

Presented By: Dalia Kaakour, MD – University of California, Irvine Date: Aug 12, 2023 In the realm of oncology and immunotherapy, the investigation into the safety and efficacy of immune checkpoint inhibitors (CPIs) takes a step forward with an insightful study by Dr. Dalia Kaakour, MD, MPH, from the University of California, Irvine’s Department of Medicine Division of Hematology and Oncology Fellowship Program. With an absence of any disclosures, this study delves into the realm of immune-related adverse events (irAEs) in patients afflicted by both solid tumors and advanced chronic kidney disease (CKD) who are undergoing treatment with CPIs. Traditionally,…

Presented By: Shirin Attarian, MD Date Aug 12, 2023 In the realm of oncology, Head and Neck Cancer stands as a significant challenge, both in terms of its prevalence and the intricacies surrounding its diagnosis and treatment. This complex and diverse set of malignancies affects millions across the globe each year, making it the seventh most common cancer worldwide. Amid the countless battles against this formidable adversary, the insights of medical professionals like Dr. Shirin Attarian have proven invaluable. Dr. Attarian’s meticulous review of Head and Neck Cancer reveals a landscape of statistics that underscore the urgency of continued research…

Alexander Edward Perl, MD, MS – Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania Alexander Edward Per, MD, MS emphasizes the need to unravel the intricacies of both primary and secondary resistance mechanisms associated with FLT3 inhibitors, highlighting their role in AML management. Discussions revolve around the potential of these inhibitors to target FLT3 mutations, while also addressing challenges such as polyclonality and the selection of resistant clones. The importance of achieving optimal disease response is underscored, with an emphasis on utilizing minimal residual disease (MRD) testing to guide treatment decisions and enhance patient outcomes. REGISTER…

Farhad Ravandi, MD is Janiece and Stephen A. Lasher Professor of Medicine and Chief of Section of Developmental Therapeutics in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. In his compelling presentation, Farhad Ravandi, MD, a distinguished medical professional in the field of oncology, delves into the critical significance of minimal residual disease (MRD) assessment in the realm of acute myeloid leukemia (AML) treatment. As an accomplished hematologist, Dr. Ravandi brings his extensive expertise to the forefront, elucidating how achieving complete morphological remission is a pivotal determinant in long-term survival for AML patients. REGISTER NOW…

Refresh URL Changing Content

Spotlight on Oncology: Exploring the Latest Advances in Lung Cancer Research Date: August 12, 2023 Speaker: Sai-Hong Ignatius Ou, MD PhD Welcome to the 2023 MAOSC Spotlight on Oncology, a dynamic event that brings together leading minds in the field of lung cancer research to discuss groundbreaking developments and insights. This year’s event focuses on the latest advancements in lung cancer treatment, with a special emphasis on the management of lung cancer through various stages. At the helm of this enlightening discussion is the esteemed Dr. Sai-Hong Ignatius Ou, MD PhD. Dr. Ou is a distinguished Health Science Clinical Professor…

Updates in Lymphoma: Advancements in Treatment Strategies Date: August 12, 2023Presenter: Elizabeth Brem, MD (Clinical Associate Professor) In the ever-evolving landscape of oncology, particularly in the field of lymphoma treatment, significant strides have been made to improve patient outcomes and quality of life. Dr. Elizabeth Brem, a prominent figure in the field, delivered a comprehensive presentation on the recent updates in lymphoma treatment during the recent event. Dr. Brem is a Clinical Associate Professor renowned for her expertise and contributions to the field. Disclosures: Dr. Elizabeth Brem is associated with several pharmaceutical and biotech companies, reflecting her active engagement in…

Interview with Pankit Vachhani, MD Hematology Oncology- UAB Medicine Timestamps: 0:00:09 What is the objective of this study on indolent systemic mastocytosis (ISM)?0:00:50 How were patients with ISM randomized in this study, and what were the treatment groups?0:01:48 What was the primary endpoint measured in this study, and how was it assessed?0:02:20 What were the secondary endpoints evaluated in this study?0:03:19 What were the results regarding the mean change in total symptom score (TSS) between the avapritinib and placebo groups?0:04:17 How did avapritinib treatment impact serum tryptase levels in patients with ISM?0:05:02 Were there any notable differences in adverse events…

Amir T. Fathi MD Associate Professor of Medicine, Harvard Medical School Program Director, Center for Leukemia- Massachusetts General Hospital Join us on a journey to the forefront of Acute Myeloid Leukemia (AML) treatment, guided by the expertise of Amir T. Fathi MD. In the dynamic landscape of 2023, Dr. Fathi’s insights illuminate the remarkable progress being made, specifically within the realm of IDH 1/2-mutant AML cases. This transformative approach integrates cutting-edge molecular insights and targeted therapies, revolutionizing the trajectory of AML care. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL…

Harry Paul Erba, MD Professor of Medicine Member of the Duke Cancer Institute This content features Harry Paul Erba, MD, who discusses the optimization of frontline therapy for FLT3 mutated AML patients, focusing on quizartinib’s impact. Dr. Erba explains the pivotal role of FLT3 receptor tyrosine kinase in hematopoiesis and its connection to AML blast. He details the variations in FLT3 mutations, encompassing internal tandem duplication (ITD) and TKD mutations, elucidating their distinct prognostic implications. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU…

Joseph D. Khoury, MD is the Stokes-Shackleford Professor and Chair, Department of Pathology and Microbiology, University of Nebraska Medical Center. In a dynamic presentation at the recent event, Joseph D. Khoury, MD delved into the intricate realm of Acute Myeloid Leukemia (AML), shedding light on genetic advancements, diagnostic nuances, and promising targeted therapies. The engaging discourse began with gratitude for the invitation and San Diego’s delightful weather. Coming from varied backgrounds like Houston, Texas, and even Nebraska, the speaker emphasized their unique vantage point straddling different locales. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online…

The “MOASC SPOTLIGHT ON ONCOLOGY – GU ASCO UPDATES” seminar, led by Dr. Nataliya Mar, Clinical Associate Professor in the Division of Hematology/Oncology at the University of California Irvine, August 12, 2023 This discussion marked a significant milestone in the field of genitourinary oncology. Dr. Mar’s insightful presentation delved into various scenarios, revealing the complex landscape of oncology care and the advancements in treatment strategies. At the outset, Dr. Mar disclosed her affiliations with leading pharmaceutical companies, including Seattle Genetics, Aveo, Eisai, Tempus, and Merck, which underscores the relevance of her insights and findings in the context of emerging therapies…

Pancreatic Cancer Updates – Insights from Vincent Chung, MDDiscover the latest advancements in the field of pancreatic cancer through an enlightening presentation by Dr. Vincent Chung, a distinguished figure in oncology and a consultant for Perthera. Delve into the comprehensive exploration of Pancreatic Cancer, its challenges, and the transformative approaches to treatment. This event, held on August 12, 2023, at the MOASC / UCI Spotlight on Oncology, presents crucial updates that could revolutionize the landscape of pancreatic cancer care.Understanding the Scope of the ProblemWith the unfortunate distinction of having the worst survival rates among solid tumors, pancreatic cancer poses a…

Anthony El-Khoueiry, MD. As the Associate Director for Clinical Research and Phase 1 Program Director at the prestigious USC Norris Comprehensive Cancer Center Discover the latest advancements in the field of Hepatobiliary Cancers in this comprehensive session titled “Hepatobiliary Cancers Therapeutic Updates” featuring the esteemed Anthony El-Khoueiry, MD. As the Associate Director for Clinical Research and Phase 1 Program Director at the prestigious USC Norris Comprehensive Cancer Center, Dr. El-Khoueiry brings his expertise to illuminate the cutting-edge developments in the treatment of hepatobiliary cancers.This session delves into critical topics that are reshaping the landscape of hepatobiliary cancer therapies. The intricate…

MOASC – Spotlight on Oncology Colorectal Cancer AbstractsDate: August 12, 2023Location: Huntington Beach, CAPresenter: Jason A. Zell, DO, MPHPosition: Professor, Vice Chief of Academic AffairsDivision of Hematology/Oncology, Dept. of MedicineUniversity of California Irvine In this spotlight session on oncology, the focus was on Colorectal Cancer (CRC) abstracts, with special attention given to the latest advancements and research findings. The presenter, Dr. Jason A. Zell, a distinguished figure in the field, holds the position of Professor and Vice Chief of Academic Affairs within the Division of Hematology/Oncology at the University of California Irvine. Abstracts were presented, shedding light on significant studies…

Dr. Sayeh Lavasani, MD, MSc, FRCPC, an Associate Clinical Professor in the Division of Hematology Oncology at the Department of Medicine, UCI Health, presented updates on breast cancer research during the MOASC (Medical Oncology Association of Southern California) Spotlight On Oncology. Here’s a breakdown of the key topics discussed: Presenter Disclosures: Dr. Lavasani’s disclosures include associations with Daichii Sankyo, Seagen, Sermonix, and Astrazeneca for honorarium, institutional research funding, consultation, and speaker engagements. Outline: Hormone Positive Breast Cancer: Early Stage (NATALEE) Metastatic Breast Cancer: SONIA HER2+ Breast Cancer: PHERGain (Cortes et al.) Key Highlights: Hormone Positive Breast Cancer – NATALEE Study:…

In the ever-evolving world of oncology, there is always a beacon of hope on the horizon. The latest such promise comes in the form of a drug known as Sacituzumab Govitecan. This compound, while complex in name, is pioneering some of the latest advancements in cancer treatments, particularly in the realm of Triple-Negative Breast Cancer (TNBC). What is Sacituzumab Govitecan? Every drug, from the over-the-counter solutions to groundbreaking cancer treatments, has a story to tell, often starting with its name. Sacituzumab Govitecan isn’t merely a jumble of syllables. It’s a name derived from the drug’s intricate nature and function. While…

Sanam Loghavi is Assistant Professor, Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Sanam Loghavi is an accomplished pathologist known for her expertise in the field of hematopathology and her contributions to the diagnosis and understanding of various hematologic malignancies, including acute myeloid leukemia (AML). Her work focuses on unraveling the molecular intricacies of AML and other blood disorders to enhance patient care through personalized treatment strategies. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open -…

For those with an interest in the management of acute myeloid leukemia, the conference provided a unique and valuable platform. Attendees commended the insightful talks and the lively debates that ensued, offering a wealth of perspectives and research ideas. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The sentiment expressed was overwhelmingly positive, with participants applauding the conference’s exceptional speakers, engaged audience, interactive format, and the prospect of forging new…

The discussion revolves around the complexities of Blinatumomab treatment for leukemia, with experts debating the reasons behind the partial clinical hold on cooperative group studies, concerns about combining treatments concurrently, and the potential impact of reducing chemotherapy intensity. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Topics also include the risk of CNS relapses, the significance of IT chemotherapy, and the emergence of CD19-negative relapses with Blinatumomab. The experts emphasize…

The panel discussed various aspects related to the use of next-generation sequencing (NGS) and flow cytometry for minimal residual disease (MRD) detection in patients with various types of leukemia, particularly acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). They touched upon the challenges and benefits of using NGS for detecting MRD at greater detection depths. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The question arose as to whether…

In this lively debate, experts engage in a comprehensive analysis of Nelarabine’s efficacy in the treatment of ALL. The discussion covers its benefits and drawbacks, particularly focusing on its usage in EFS and DFS within the pivotal trial. Controversial points emerge regarding its impact on survival rates, with contrasting viewpoints on its effectiveness in pediatric and adult populations. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The potential of combination…

In a dynamic and insightful debate, leading experts in the field of leukemia treatment delved into the intricacies of optimizing therapies for relapsed acute lymphoblastic leukemia (ALL). The discussion revolved around cost-effective strategies and clinical considerations for achieving enhanced outcomes. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The experts examined the potential of combining various treatments, including CAR T-cell therapy, to mitigate the escalating costs of managing relapsed ALL.…

We mourn the profound loss of Dr. Krystal Cascetta, a committed oncologist and breast cancer researcher. Our hearts extend to her family, friends, patients, and colleagues in these challenging times. In memory of her life and contributions, we highlight the severe mental health challenges faced by oncology professionals. Managing gravely ill patients, navigating intricate diseases, and daily confrontations with mortality exert a heavy emotional burden. Oncologists face higher rates of burnout, depression, and suicide compared to other physicians. It’s crucial that we foster a culture in oncology that forefronts mental health and well-being. Dr. Cascetta was not only a compassionate…

The panel discussion centered on the optimization of leukemia treatment, particularly focusing on the combination of venetoclax with various therapies. Preclinical data and pathophysiology were explored, highlighting the potential of inhibiting JAK2 mutations with venetoclax. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Concerns were raised about CNS relapse and CD19-negative relapses, emphasizing the need for continued IT chemotherapy. The balance between systemic chemotherapy reduction and comprehensive coverage with antigen-directed…

When discussing the myriad of cancers that affect humans, head and neck cancers, though slightly less talked about, remain a significant concern for medical professionals and patients alike. These cancers, which can originate in the oral cavity, throat, larynx, paranasal sinuses, and nasal cavity, are often diagnosed late due to their subtle initial symptoms. As a result, the need for effective treatments is palpable, especially for those cases where the disease has metastasized or recurred after initial treatment. Over the years, there’s been a growing interest in leveraging the body’s immune system to combat cancers, a treatment approach referred to…

The discussion centered on optimizing leukemia treatment strategies through the combination of immunotherapies and chemotherapy. The concern of CNS relapse and CD19-negative relapses was highlighted, emphasizing the importance of continued IT chemotherapy. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com While there is interest in reducing systemic chemotherapy, caution was advised due to potential resistance. The potential of combining antigen-directed therapies with chemotherapy for better coverage was discussed, along with…

This in-depth discussion among experts explores various facets of leukemia management. The conversation spans topics including challenges in clonotypable patients, the significance of MRD negativity in high-risk genetics, and the ongoing debate surrounding the necessity of transplantation for specific patient groups. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The experts also touch on practical considerations, such as the frequency of peripheral blood monitoring compared to bone marrow assessments.

Medical experts engaged in a discussion about advancing pediatric acute myeloid leukemia (AML) treatment strategies. Venetoclax, a promising drug, was a focal point, and its potential inclusion in pediatric protocols was explored. The challenge of adapting adult regimens to pediatric patients while considering drug forms suitable for children was discussed. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The importance of collaborative trials, merging efforts across pediatric and adult AML,…

Navigating the ever-evolving landscape of leukemia treatment has become an intricate endeavor, with recent clinical trials offering intriguing insights and sparking lively debates. These trials delve into the effectiveness of innovative therapies such as gilteritinib and midostaurin, potentially reshaping the foundation of standard care protocols. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Controversies emerge surrounding the significance of randomized studies in a rapidly changing environment, where salvage therapies like…

The conversation focuses on AML treatments, including arsenic and another frontline approach. Preventing relapses through non-toxic drugs like masitinib is explored. Financial obstacles and customized treatments are discussed. The importance of precise timing for treatments is highlighted. Myelosuppression and new dosing ideas are brought up. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Clinical trial design’s role in optimizing treatment is mentioned, with examples of challenges in drug approval. The need…

In this discussion, the focus is on optimizing Acute Myeloid Leukemia (AML) treatment. The idea of reducing drug doses upon achieving remission is challenged, questioning its efficacy against resistant disease. The notion of increasing drug doses to target resistance for improved outcomes is proposed. Perspectives diverge, with one side highlighting the need for conservative dosing to manage toxicities, while the other suggests early, aggressive intervention. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus…

Leading experts engage in a comprehensive discussion on the intricate landscape of long-term remission and resistance patterns in transplanted acute myeloid leukemia (AML) patients, focusing on the potential role of Menin Inhibitor maintenance therapy. The dialogue delves into post-transplant outcomes and the emergence of resistance mutations, referencing previous presentations at the American Society of Hematology (ASH) meeting. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Central topics include the distinction…

Ryan Fitzpatrick, CEO, MD Education In opening the Focus Meeting 2023, Ryan Fitzpatrick, CEO, expresses gratitude to attendees and collaborators for their efforts. The importance of gathered speakers is emphasized, promising insightful discussions. Professional conduct and the value of fellows and junior faculty members are underscored. Logistical details, including breaks and a dinner, are outlined. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Online resources’ availability is noted, extending the…

The discussion revolves around complex topics related to acute myeloid leukemia (AML), including its groups, molecular markers, patient eligibility for clinical trials, and considerations of germline predisposition. Participants delve into the challenges of defining AML subtypes, the significance of molecular markers in diagnosis and treatment decisions, and the potential impact of germline factors on patient outcomes. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The conversation also touches on the…

In the ever-evolving landscape of medical science, melanoma and Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) have remained two of the most formidable cancers to treat. Both of these cancers present unique challenges due to their aggressive nature and high recurrence rate. Yet, in the shadow of these challenges, targeted therapies have emerged as a beacon of hope. Targeted therapies are a relatively new addition to the oncological toolkit. Unlike traditional treatments that indiscriminately target both healthy and cancerous cells, targeted therapies focus precisely on the specific genes and proteins that are involved in the growth…

Joseph D. Khoury, MD is the Stokes-Shackleford Professor and Chair, Department of Pathology and Microbiology, University of Nebraska Medical Center. Joseph Corey, MD, Chair of Pathology and Microbiology at the University of Nebraska Medical Center, Omaha, presented a seminar on acute myeloid leukemia (AML) classification and its genetic underpinnings. The conference offered a platform for AML physicians and diagnostic specialists, like Corey, to exchange insights. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus…

Harry Paul Erba, MD Professor of Medicine and Member of the Duke Cancer Institute Harry Erba, MD, a respected Duke University Medicine Professor, refines intensive chemotherapy for FLT3 mutated AML patients. He validates Midostaurin’s potential via the RATIFY trial and now focuses on potent second-gen FLT3 inhibitors. In the quantum first study, quizartinib enhances ITD mutated AML survival, particularly in younger patients (hazard ratio 0.68). Older patients also benefit, though less significantly (hazard ratio 0.9). REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU…

Amir Fathi, MD Associate Professor of Medicine, Harvard Medical School Program Director, Center for Leukemia- Massachusetts General Hospital. Amir Fathi MD, an esteemed professional at Massachusetts General Hospital in Boston, Massachusetts, recently delivered a noteworthy presentation at a conference. His talk centered on induction strategies within the realm of patients lacking FLT3 mutations, showcasing the breadth of his expertise. The event proved to be a platform for various experts, including Amir’s colleagues, who shared compelling data. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration…

Alexander Edward Perl, MD, MS is a member of the leukemia program in the Abramson Cancer Center of the University of Pennsylvania and an Associate Professor of Medicine at the Perelman School of Medicine. Alexander E. Perl, MD, MS, an associate professor in the leukemia program at the Abrams Cancer Center, University of Pennsylvania, recently presented at a conference. He discussed identifying resistance mechanisms in FLT3 mutated AML patients and shared data-driven strategies for improved treatment. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/…

Courtney D. DiNardo, MD, MSCE Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Courtney DiNardo, MD, from MD Anderson Cancer Center, discussed IDH inhibitor therapy at a recent conference. She emphasized the benefits of combining IDH inhibitors with other treatments, showcasing a promising triplet therapy involving azacitidine, venetoclax, and IDH inhibitor. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com…

Eytan M. Stein, MD – Leukemia & Early Drug Development Specialist – David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center Eitan M. Stein, MD, Chief of the Leukemia Service at Memorial Sloan Kettering Cancer Center in New York City, delivered a presentation on the utilization of menin inhibitors in treating acute leukemia. The focus was on their application in patients with KMT2A rearrangements and NPM1 mutations. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/…

Naval G. Daver, MD is an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center. Naval G. Daver, MD, a faculty member at MD Anderson Cancer Center, co-chaired a successful symposium in Houston, Texas, featuring engaging presentations and active participation from junior faculty. Naval’s presentation focused on groundbreaking triplet therapies for acute myeloid leukemia patients unable to undergo intensive chemotherapy. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023…

Brian Andrew Jonas, MD, Ph.D. Associate Professor of Medicine (Clin X) – UC Davis Comprehensive Cancer Center Brian Jonas MD, Ph.D. from U.C. Davis sheds light on the latest advancements in AML treatment, focusing on the practical management of HMA Venetoclax. He delves into standard care approaches, recent progress, dosing adjustments, and toxicity mitigation. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Sharing insights from prominent thought leaders at the conference,…

Marina Konopleva, M.D., Ph.D. Professor, Department of Oncology (Medical Oncology) and Department of Molecular Pharmacology Albert Einstein College of Medicine Jack and Pearl Resnick Campus Marina Konopleva, MD, PhD, is a distinguished name in the realm of medical research, serving as the Director of Leukemia at the renowned Einstein Medical Center in New York. With an esteemed cross-appointment at both Ambient’s and Casanthe, Licky Merplatte, Marina Konopleva stands as a prominent authority in the study of leukemia and its intricate treatment mechanisms. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU -…

Hi Nkem – I just wanted to reach out and introduce myself. I’m Allen Wilbanks here at OncologyTube. It seems our company aligns with Sanofi’s commitment to advancing oncology research and treatments. So I’m leaving my calendar link here: https://meetings.hubspot.com/allen12 Please book a date if you think it would be worth your time to chat. Thank you in advance. Cheers, Allen Wilbanks allen@oncologytube.com (951) 326-8827

Hi Maria, I’m Allen Wilbanks and I’m taking over all of Scott Nasiff’s accounts here at OncologyTube and I thought I’d reach out and introduce myself. I know you were working with Scott on the Takeda Oncology account last year and from this point forward I’ll be your contact here at OncologyTube. I would love to hear about your new projects so I’m including a link to my calendar here. https://meetings.hubspot.com/allen12 Cheers, Allen Wilbanks allen@oncologytube.com (951) 326-8827

Hi Frances, Hope you are well. You had reached out to OncologyTube on July 4th and I sent you some initial information about us such as we reach 35,000 HCP per month mainly oncologists and hematologists, in addition you asked us about our geographic reach. I just wanted to reach back out and say hi and ask if you have any more questions? If so please don’t hesitate to book an appointment with me here… https://meetings.hubspot.com/allen12 Cheers, Allen Wilbanks allen@oncologytube.com (951) 326-8827

Breast cancer is a topic that has garnered significant attention over the years, and for good reason. Affecting millions worldwide, it remains one of the most common forms of cancer among women. While early detection and advancements in treatment have improved prognosis for many, metastatic breast cancer (MBC) remains a significant challenge in the oncology world. By definition, metastatic breast cancer is when cancer has spread beyond the breast and axillary lymph nodes to other parts of the body. This form of cancer, often referred to as stage IV breast cancer, necessitates a deeper understanding and exploration of treatment options.…

Hi Dina, just wanted to say and let you know that we just registered for SABCS 2023 so we will be there if you need anything filmed. Also, we are ready whenever you are to launch the video pre-roll campaign or banners. Looking forward to working with you. Cheers, Allen

Farhad Ravandi-Kashani, M.D. Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Farhad Ravandi, MD a distinguished professor of medicine at the University of Texas MD Anderson, delivered a captivating presentation on advancing disease assessment in AML patients at a recent conference. Professor Ravandi emphasized the significance of utilizing advanced tools and assays to detect residual leukemia, as emerging data strongly link any remaining leukemia cells to a heightened risk of relapse and poorer outcomes. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available -…

Marlise R. Luskin, MD, MSCE is a physician in Dana-Farber’s Adult Leukemia program. Meet Marlise Luskin, MD, MSCE, an esteemed Assistant Professor of Medicine and Senior Physician at Dana-Farber Cancer Institute in Boston, Massachusetts. With a focus on acute lymphoblastic leukemia, Marlise sheds light on the pivotal role of venetoclax in its treatment. Through insightful analysis of preclinical evidence, she explores the drug’s potential sensitivity against the disease, particularly when paired with diverse chemotherapy agents. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS…

Nitin Jain, MD. Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Nitin Jain, MD delved into the intricacies of T-cell Acute Lymphoblastic Leukemia (T-ALL). He highlighted the pressing medical void in this area and underscored the advent of innovative therapies. In particular, he focused on Chimeric Antigen Receptor T-cell (CAR-T) therapies, which hold immense promise for patients. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL…

Regina Myers, MD, MSCE, is an instructor in the Cancer Center at Children’s Hospital of Philadelphia. Regina Myers, MD, MSCE discusses novel approaches within the context of CAR T-cell therapy to address the challenge of relapse, which is when cancer returns or resists treatment after an initial response. The two main mechanisms of relapse that she focuses on are loss of persistence (the CAR T cells’ ability to remain effective over time) and antigen modulation (changes in the cancer cells that make them less recognizable to CAR T cells). REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US…

Shira N. Dinner, MD. Associate Professor, Medicine, Hematology Oncology Division; Feinberg School of Medicine Sherra Diner, MD, an esteemed associate professor and leukemia physician at Northwestern University in Chicago, delves into a compelling discussion regarding the treatment of elderly adults with ALS. She emphasizes a departure from conventional chemotherapy approaches, advocating for the adoption of chemo-free and chemo-lite regimens. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Notably, the talk…

Hagop M. Kantarjian, MD. Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX In the featured video, renowned expert Hagop Kantarjian, MD, a professor at MD Anderson Cancer Center, delves into groundbreaking developments in the treatment of adult acute lymphoblastic leukemia (ALL). With a focus on cutting-edge strategies, including third-generation TKIs like Ponatinib and Blinatumomab, as well as CD19/CD22-targeting antibodies, Hagop Kantarjian, MD underscores their promising potential to elevate cure rates while diminishing the demand for intensive chemotherapy. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online…

Tapan M. Kadia, MD. Professor, Department of Leukemia, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX Tapan Kadia, MD, a professor at MD Anderson Cancer Center, discusses acute myeloid leukemia (AML) maintenance therapy at the MD Education Conference. He highlights azacitidine as a standard treatment. After exploring various post-consolidation strategies, hypomethylating agents have emerged, extending remissions after stem cell transplantation. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com…

Bijal Shah, MD, MS Hematology/Oncology H. Lee Moffic Cancer Center In the video, Bijal Shah, MD, MS discusses the significance of CAR T-cell therapy in treating B-cell Acute Lymphoblastic Leukemia (B-ALL) at the H. Lee Moffic Cancer Center. Shaw emphasizes the need to integrate CAR T-cell therapy early with novel agents, particularly in low disease burden scenarios, to improve outcomes for adults with B-ALL. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting…

Aaron Logan, MD – Associate Professor of Clinical Medicine at the University of California, San Francisco (UCSF) Meet Aaron Logan, MD Associate Professor of Clinical Medicine at the University of California San Francisco, who presented on the use of MRD (Minimal Residual Disease) to guide therapy in adults with acute lymphoblastic leukemia. In the evolving landscape of leukemia treatment, with blinatumomab moving to the forefront and the ECOG nineteen ten study showcasing benefits for patients achieving MRD negativity at the level of ten to the minus four, Aaron highlights the increasing importance of MRD assessment using high sensitivity NGS…

Anjali Advani, MD – Hematology and Medical Oncology – Cleveland Clinic Meet Anjali Ifani, MD the esteemed Director of the Inpatient Leukemia Unit at the renowned Cleveland Clinic. At a recent conference, she delivered an engaging talk on the integration of immunotherapy into front-line therapy for leukemia. Anjali also participated in a lively debate with Dr. Cassidy, focused on the incorporation of Blinatumumab versus Inetuzumab in frontline leukemia therapy. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register…

Elias Jabbour, MD – Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX This conference has been an outstanding success, bringing together a diverse and knowledgeable group of experts for engaging discussions and thought-provoking questions. The organization by the MD Education team was seamless and highly professional, and the choice of location was exceptional. Attendees expressed great satisfaction with the faculty’s presentations, which allowed ample time for in-depth discussions, debates, and sharing of viewpoints. The event provided a fantastic platform for networking with colleagues and peers while also benefiting from the expertise of specialists in…

Esophageal adenocarcinoma is a subtype of cancer that arises from the glandular cells in the esophagus, the muscular tube responsible for moving food from the mouth to the stomach. Known to be one of the most aggressive and potentially lethal forms of cancer, esophageal adenocarcinoma has become a major concern in oncology. According to the American Cancer Society, the incidence of this malignancy has been increasing, particularly in Western countries. With a rising prevalence, understanding and addressing esophageal adenocarcinoma become crucial. This involves recognizing the disease’s complexity, from its pathology to the effectiveness of current treatments. An urgent need for…

Dr. Kevin Harrington, Phd of the Royal Marsden Hospital, The Institute of Cancer Research, London, is the author of this OncologyTube.com video. August 5, 2023 Timestamps: 0:29 Why are ipilimumab and nivolumab used together? 0:39 What was the objective of the phase II CheckMate 714 trial? 1:40 How many patients were included in the trial, and what were the inclusion criteria? 3:23 What were the treatment regimens tested in the trial? 4:06 What were the primary endpoints of the trial? 5:33 Did the addition of ipilimumab to nivolumab improve the objective response rate in patients with recurrent or metastatic squamous…

Chronic Lymphocytic Leukemia (CLL), a type of cancer that begins in the bone marrow and invades the blood, is one of the most common adult leukemias. Affecting mainly older adults, it’s a condition that has seen a significant shift in treatment approaches and understanding over the years. CLL is a slow-growing leukemia where the bone marrow makes too many lymphocytes (a type of white blood cell). Unlike acute leukemias, CLL develops gradually and might not cause symptoms for a long time. It can be especially complex to manage in its previously untreated stage, as it may present unique challenges in…

Ann M. Gillenwater, MD – MD Anderson, Department of Head and Neck Surgery, Division of Surgery presents the First Safety and Efficacy Data of the Rakuten Medical Alluminox Treatment using ASP-1929 in Combination with anti-PD-1 for Recurrent and/or Metastatic Head and Neck Cancer at AHNS 2023. Questions: Can you please summarize the Phase 1b/2 study ASP-1929-181 that you presented this week at the American Head & Neck Cancer Society 2023 meeting? Can you please explain the Alluminox technology? Can you provide our viewers with information about any other Alluminox ASP-1929 data in head and neck cancer? Can you talk about…

Barbara Eichhorst, MD Professor of Medicine at UNIVERSITÄTSKLINIKUM KÖLN, is the author of this OncologyTube.com video. Timestamps: 0:09 Can you tell us about the CELL Trial and it´s design and any significant data. 3:04 How many patients were enrolled in the study and what were the characteristics of the patient population? 3:55 Can you touch on any adverse events that were seen in the study? 5:18 What are the common questions you’re asked by your colleagues about this data? 6:59 What are the key takeaways that you’d like to leave are oncologists viewers with and any final thoughts? 7:45 Is…

In this video, Dr. Samuel Klempner, MD summarizes the phase 3 STAR-221 clinical trial investigating a novel treatment for advanced upper gastrointestinal cancers.The STAR-221 study is comparing the combination of the immunotherapies domvanalimab, zimberelimab, and chemotherapy against standard chemotherapy plus nivolumab. It is enrolling over 700 patients with untreated, metastatic gastric, GE junction, or esophageal adenocarcinoma.The co-primary endpoints are progression-free and overall survival. Key secondary endpoints include response rate, duration of response, and safety. Dr. Klempner provides high-level overviews of the preliminary efficacy and safety data from the trial.He also discusses how PD-L1 expression is being analyzed to determine which…

Anju Replacement

Virginia Kaklamani, MD – UT Health San Antonio discusses Elacestrant (ORSERDU), an oral endocrine therapy, has been approved by the FDA for the treatment of advanced or metastatic breast cancer with ESR1-mutations. These mutations are found in up to 40% of tumors in estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. A previous analysis showed that patients with ESR1-mut tumors who had prior CDK4/6 inhibitor (CDK4/6i) exposure for at least 12 months experienced a median progression-free survival (PFS) of 8.6 months with elacestrant compared to 1.9 months with standard of care (SOC).A new analysis of the…

Sarbajit Mukherjee, MD, MS, Assistant Professor, Roswell Park Comprehensive Cancer Center conducted a study to investigate the efficacy of a novel treatment approach for localized esophagogastric adenocarcinoma (EGAC). The standard treatment of pre-operative chemoradiation (CRT) followed by surgery leads to a pathologic complete response (pCR) rate of 20%. However, achieving pCR is associated with improved overall survival (OS). In this study, physicians aimed to increase the pCR rate by administering an innovative combination of FTD/TPI and oxaliplatin as induction chemotherapy (IC) prior to standard CRT.Between January 2020 and October 2022, patients eligible for potentially curative surgery with EGAC were enrolled…

Tune in to the 2022 Targeted Therapies Forum to explore the critical role of nutrition in cancer treatment, discussed by leading oncologists Drs. Desai, Khalil, Preeshagul, Luo, and Terri Conneran. This enlightening discussion sheds light on the importance of dietary considerations in managing the side effects and boosting the effectiveness of cancer treatment protocols. The experts delve into practical strategies, evidence-based nutritional interventions, and the latest research findings on the subject, offering valuable insights for healthcare professionals involved in oncology. This invaluable resource is brought to you with support from our sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech.…

Navigating the world of cancer care requires ample support for patients and their caregivers. In this enlightening video, Dr. Aakash Desai and Terri Conneran share invaluable insights on how to find the essential resources that empower patients and caregivers throughout the cancer treatment journey. Special thanks to our esteemed sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, who make it possible to provide this critical guidance. For more informative videos like this and to join a community of professionals dedicated to improving cancer care, please visit cancerGRACE.org. To engage in conversation with peers and experts in the field, visit…

Opening up to loved ones about a cancer diagnosis is a deeply personal and often challenging experience. In this thought-provoking session, Drs. Preeshagul, Khalil, Luo, and Terri Conneran offer compassionate guidance on how to approach this sensitive conversation. With the generous support from our sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, we’re able to bring you this crucial dialogue. Whether you’re facing this situation yourself or supporting someone close to you, we invite you to explore further resources and engage with others who understand your journey. Visit cancerGRACE.org for more, and to join the conversation, visit https://cancergrace.org/forum.

Understanding when to adjust cancer treatment is paramount in patient care. In this crucial session, Drs. Desai, Khalil, and Luo shed light on the indicators, strategies, and considerations that guide the decision to change treatment during cancer progression. Supported by our committed sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, this video offers essential insights for patients, caregivers, and healthcare professionals. For further guidance, resources, and community support, please visit cancerGRACE.org. To engage with experts and peers on this vital subject, join the conversation at https://cancergrace.org/forum.

The landscape of treating KRAS+ NSCLC (Non-Small Cell Lung Cancer) is evolving, and understanding how to approach patient care after progression on Sotorasib is vital. In this specialized segment of the 2022 Targeted Therapies Forum, Dr. Jia Luo provides an in-depth examination of therapeutic options for patients who have progressed on Sotorasib. This session is brought to you by our esteemed sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, who enable us to offer invaluable insights to the medical community. For further information on this topic and other related fields in oncology, please visit cancerGRACE.org. To engage with experts,…

Handling the stress associated with cancer scans is a vital aspect of care for both patients and healthcare professionals. In this enlightening session of the 2022 Targeted Therapies Forum, Panelists Conneran, Khalil, Luo, Desai, and Preeshagul shed light on innovative and compassionate methods of stress reduction involving scans. This session is proudly supported by our sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, who make such essential discussions possible. For more comprehensive information on this topic and to explore a treasure trove of resources related to cancer treatment, care, and therapies, please visit cancerGRACE.org. Join the conversation, share your…

Drs. Khalil, Luo, Desai, and Preeshagul in this insightful video from the 2022 Targeted Therapies Forum as they discuss effective methods for stress reduction involving scans for newly diagnosed patients. Their expert advice offers support, guidance, and practical strategies to ease the emotional toll of diagnosis. Supported by our sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, this video is a must-watch for patients, caregivers, and healthcare professionals alike. For more resources and to join the conversation, please visit http://cancerGRACE.org/ or follow the discussion at https://cancergrace.org/forum. Don’t miss the opportunity to learn from leading experts in the field, and…

Dr. Maya Khalil dives into the intricacies of RET+ NSCLC treatments in our 2022 Targeted Therapies Forum. Gain insights as she meticulously compares the efficacy and application of Selpercatinib and Pralsetinib, two leading medications in the field. Supported by our esteemed sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. For a deeper understanding and to be a part of the larger conversation on RET+ NSCLC, make sure to visit http://cancerGRACE.org/. Engage with experts and peers in our forum: https://cancergrace.org/forum.”

In the esteemed 2022 Targeted Therapies Forum, Dr. Jia Luo, renowned Medical Oncologist from Dana-Farber Cancer Institute and respected Instructor in Medicine at Harvard, alongside Dr. Isabel Preeshagul, Thoracic Medical Oncologist from Memorial Sloan Kettering, dives deep into the realm of KRAS Treatments and Clinical Trials. Specifically, Dr. Jia Luo sheds light on the treatment pathways for KRAS+ NSCLC and provides insights on navigating the complex landscape of clinical trials. Grateful for the support from our sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. To explore more on the latest cancer treatments and engage with a vibrant community, do…

In an inspiring session from the 2022 Targeted Therapies Forum, Terri Conneran, lung cancer survivor and the visionary Founder of KRAS Kickers, shares her profound journey battling KRAS+ NSCLC. Delve into Terri’s story as she unravels the motivation behind establishing KRAS Kickers, a beacon of hope and community for countless others navigating similar health challenges. Special thanks to our valued sponsors for making this enlightening session possible: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. To uncover more insightful stories and groundbreaking discoveries in the world of cancer research, please visit http://cancerGRACE.org/. Engage with experts, survivors, and advocates at https://cancergrace.org/forum.

Dive deep into the world of RET+ NSCLC treatment options with Dr. Maya Khalil, an esteemed Hematology-Oncologist from the Kirklin Clinic of UAB Hospital and an Assistant Professor of Medicine at the University of Alabama at Birmingham. As part of the 2022 Targeted Therapies Forum, Dr. Khalil offers her unparalleled expertise in managing RET Mutated NSCLC, shedding light on the most effective treatments for patients diagnosed with RET+ NSCLC. A heartfelt thank you to our distinguished sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech for their unwavering support. Yearning for more? Unlock a treasure trove of insights and groundbreaking…

Join Dr. Maya Khalil, renowned Hematology-Oncologist from Kirklin Clinic of UAB Hospital and Assistant Professor at the University of Alabama at Birmingham, as she delves into the intricate realm of RET+ NSCLC. In this exclusive segment from the 2022 Targeted Therapies Forum, Dr. Khalil demystifies the processes behind detecting RET mutations and offers insights into the typical profiles of patients who carry these mutations. A big shoutout to our prestigious sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech for backing this endeavor. Hungry for more cutting-edge discussions and breakthroughs in the field of oncology? Make sure to explore http://cancerGRACE.org/.…

Delve deep into the world of RET+ NSCLC with Dr. Maya Khalil, a distinguished Hematology-Oncologist from the Kirklin Clinic of UAB Hospital and an Assistant Professor at the University of Alabama at Birmingham. In this revealing segment from the 2022 Targeted Therapies Forum, Dr. Khalil offers an illuminating case study of a patient she treated, shedding light on the intricacies of RET+ NSCLC and the complexities of gene alterations. We extend our gratitude to our esteemed sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech for their unwavering support. Eager to dive deeper into oncology’s evolving landscape? Make your way…

Unveiling the latest insights on KRAS+ NSCLC, join Dr. Jia Luo, an esteemed Medical Oncologist at Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard, in this riveting session from the 2022 Targeted Therapies Forum. Dr. Luo delves deep into the nuances of managing KRAS Mutated NSCLC, exploring state-of-the-art treatment strategies to benefit patients diagnosed with KRAS+ NSCLC. A special thank you to our generous sponsors for their support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Stay at the forefront of oncological advancements. Dive deeper into our resources at http://cancerGRACE.org/. Engage with pioneers in the field and be…

Decoding the complexities of biopsies for KRAS+ NSCLC, join Dr. Jia Luo, a prominent Medical Oncologist at Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard, in this informative session from the 2022 Targeted Therapies Forum. With an in-depth look into KRAS Mutated NSCLC management, Dr. Luo specifically shines a light on the various biopsy types crucial for KRAS diagnosis. Heartfelt gratitude to our esteemed sponsors for their unwavering support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. For a broader spectrum of resources and insights in the realm of oncology, visit http://cancerGRACE.org/. Join our vibrant community and engage…

Demystifying treatment timelines for KRAS+ NSCLC, the 2022 Targeted Therapies Forum presents Dr. Jia Luo, an esteemed Medical Oncologist from Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard. Dive deep into the intricacies of KRAS Mutated NSCLC management as Dr. Luo meticulously outlines the treatment timelines for patients diagnosed with KRAS+ NSCLC in this enlightening English edition. A massive shoutout to our revered sponsors who have been instrumental in bringing this knowledge to you: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Expand your horizons in oncological treatments and breakthroughs by visiting http://cancerGRACE.org/. Engage, inquire, and connect with…

Explore the landscape of KRAS+ NSCLC treatment in the 2022 Targeted Therapies Forum with Dr. Jia Luo, a distinguished Medical Oncologist from Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard. In this enlightening video, Dr. Luo delves into the prevalence of KRAS+ NSCLC and charts the transformative journey of its treatments over the years. Special thanks to our invaluable sponsors for their unwavering support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Stay informed with the latest in oncology research and insights. Visit http://cancerGRACE.org/ and become an active part of our thriving community at https://cancergrace.org/forum.

Dive deep into the world of Next-Generation Sequencing (NGS) tests in our 2022 Targeted Therapies Forum’s breakout session. Esteemed oncologists Dr. Seetharamu and Dagogo-Jack elucidate the contrasts between RNA and DNA testing methodologies for NSCLC. Unravel the intricacies, advantages, and clinical implications of each method, providing clinicians and patients with a clearer perspective on these critical diagnostic tools. We extend our gratitude to our steadfast sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Stay at the forefront of oncological advancements. Visit http://cancerGRACE.org/ and engage in insightful discussions at https://cancergrace.org/forum.

Welcome to the 2022 Targeted Therapies Forum’s breakout session, where renowned oncologist Dr. Dagogo-Jack delves into the nuances of BRAF and NTRK inhibitors and their pivotal role in early-stage NSCLC. Navigate the intricate pathways of these targeted treatments and understand their transformative potential in revolutionizing the landscape of non-small cell lung cancer (NSCLC) care. Heartfelt appreciation to our dedicated sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. To stay updated on cutting-edge advancements in oncology, please visit http://cancerGRACE.org/. Engage, discuss, and share your insights with a community of experts at https://cancergrace.org/forum.

Delving into the intricate landscape of NSCLC management, the 2022 Targeted Therapies Forum presents a dedicated breakout session on ‘First Line Therapy for BRAF+ and NTRK+ NSCLC’. Join Dr. Seetharamu and Dagogo-Jack as they elucidate the strategies, challenges, and groundbreaking advancements surrounding BRAF and NTRK targeted treatments for non-small cell lung cancer. A huge shoutout to our esteemed sponsors for their unwavering support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Stay at the forefront of oncological innovations by visiting http://cancerGRACE.org/. Join our vibrant community of professionals and enthusiasts, and partake in enriching discussions at https://cancergrace.org/forum.

In a specialized breakout session from the 2022 Targeted Therapies Forum, Dr. Nagashree Seetharamu delves deep into the world of NTRK+ NSCLC treatment. Learn the intricacies of two promising medications, Larotrectinib & Entrectinib, that are setting new benchmarks in the realm of non-small cell lung cancer therapies. Special thanks to our committed sponsors for their continual support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. For cutting-edge insights and groundbreaking discoveries in oncology, ensure to visit http://cancerGRACE.org/. Engage with a community of experts and fellow enthusiasts by joining the conversation at https://cancergrace.org/forum.

Dive into the intricacies of NTRK mutations in non-small cell lung cancer with Dr. Nagashree Seetharamu in this enlightening session from the 2022 Targeted Therapies Forum. Uncover why testing for NTRK mutations is pivotal, and explore the various methodologies employed in the process. Our heartfelt gratitude to our esteemed sponsors for championing this cause: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Stay at the forefront of oncology research and breakthroughs. Visit http://cancerGRACE.org/. Engage with experts and a community driven by the same passion. Join the conversation at https://cancergrace.org/forum.

Ever wondered about the nuances of NTRK mutations in oncology? Join Dr. Nagashree Seetharamu in this enlightening session from the 2022 Targeted Therapies Forum as she delves deep into the specifics of NTRK mutations and their role in cancer. A special thanks to our dedicated sponsors for making this knowledge sharing possible: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. For a deeper dive into the latest in cancer research and treatments, visit http://cancerGRACE.org/. Connect with experts and a community dedicated to understanding and battling cancer. Engage with us at https://cancergrace.org/forum.

Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Ibiayi Dagogo-Jack examines whether BRAF/MEK combination treatment works in all BRAF+ mutations. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Alejandro Calvo and Jeffrey Thompson answer a question regarding hormonal therapy and cancer treatment. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Targeted Therapies Forum 2022, Breakout Session: In this video, Drs. Calvo and Thompson discuss Crizotinib as adjuvant treatment for ROS1+ disease, and the importance of genetic testing overall. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Targeted Therapies Forum 2022, Breakout Session: In this video, Drs. Calvo and Thompson discuss when to use targeted therapy in HER2+ disease, and possible upcoming trials. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Alejandro Calvo answers a question regarding developing a second mutation with ROS1. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Jeffrey Thompson examines results from several trials for HER2+ NSCLC treatments. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Jeffrey Thompson looks at HER2+ NSCLC closely, including treatment options. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Jeffrey Thompson discusses the evolving field of NSCLC treatment, and the importance of targeted therapies. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Alejandro Calvo examines the use of chemotherapy and immunotherapy in ROS1+ NSCLC. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Dive into the ever-evolving world of ROS1+ treatment options with Dr. Alejandro Calvo. In this specialized session from the 2022 Targeted Therapies Forum, learn about the potential benefits of Lorlatinib and Repotrectinib for patients grappling with ROS1+ disease. Our gratitude goes out to our esteemed sponsors for their unwavering support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Craving more insights on cutting-edge cancer treatments? Explore http://cancerGRACE.org/. Engage with our passionate community and renowned experts at https://cancergrace.org/forum.

Unravel the complexities of ROS1+ NSCLC treatment with Dr. Alejandro Calvo. In this illuminating segment from the 2022 Targeted Therapies Forum, delve into the details of Crizotinib and Entrectinib — two promising medications championed for ROS1+ NSCLC care. We’d like to express our heartfelt gratitude to our incredible sponsors for their continued support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Eager to delve deeper into the realm of innovative cancer treatments? Discover more at http://cancerGRACE.org/. Engage with our dynamic community and leading experts at https://cancergrace.org/forum.

Dive deep into ROS1+ NSCLC with Dr. Alejandro Calvo. In this captivating segment from the 2022 Targeted Therapies Forum, gain a comprehensive understanding of ROS1 mutations, the diagnostic tests employed, and the cutting-edge treatment options available. Special thanks to our esteemed sponsors for making this knowledge sharing possible: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. To journey further into the world of advanced cancer therapies and join in the discussion with experts and peers, explore more at http://cancerGRACE.org/ and visit our forum at https://cancergrace.org/forum.

Experience the transformation of lung cancer treatment over the years with Dr. Alejandro Calvo. This 2022 Targeted Therapies Forum session provides an insightful examination into how first-line treatments for NSCLC have evolved, adapting to new discoveries and technological advancements. We express our gratitude to our prestigious sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Their support is pivotal in continuing this essential dialogue. To delve deeper into the vast world of cancer research and treatments, and to connect with a community dedicated to understanding and combating this disease, visit http://cancerGRACE.org/ and engage at https://cancergrace.org/forum.

Considering traveling for a clinical trial? Before you pack your bags, get expert insights from Dr. Angel Qin in this 2022 Targeted Therapies Forum. Dr. Qin delves into the many factors that potential participants should weigh when considering travel for a trial, helping patients and families make informed decisions about their treatment journey. Special thanks to our esteemed sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech for their unwavering support in our mission to inform and connect the cancer community. To delve deeper into the intricate world of cancer treatments, research, and patient experiences, visit http://cancerGRACE.org/. Join our community…

Disease progression in cancer treatments can be complex, especially when it comes to commonly used medications like Lorlatinib or Osimertinib. Dive deep into this crucial topic with Dr. Millie Das and Angel Qin in the 2022 Targeted Therapies Forum. Unravel the intricacies of how these medications work, why there might be progression, and what steps can be taken next. We are deeply thankful to our sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech for their commitment to fostering patient education and advocacy. To further your knowledge on the evolving landscape of cancer treatments and therapies, head over to http://cancerGRACE.org/.…

Uncommon mutations present unique challenges in cancer treatments, especially when it comes to EGFR mutations. In the 2022 Targeted Therapies Forum, Dr. Angel Qin and Millie Das provide a comprehensive breakdown of the treatment protocols for these mutations and delve into the intricate issues surrounding insurance complications for mutation testing. Our gratitude extends to our supportive sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, for their dedication to the betterment of cancer research and patient care. Stay informed and ahead in the evolving landscape of cancer treatments. Explore more insights at http://cancerGRACE.org/. For an interactive experience, join our community…

As cancer treatment progresses, managing side effects becomes paramount. In this insightful session from the 2022 Targeted Therapies Forum, Drs. Millie Das and Angel Qin share expert recommendations on treating mouth sores, a common yet distressing side effect. Additionally, for those looking to mitigate other side effects, they guide viewers on finding relevant clinical trials that offer promising solutions. A big thank you to our esteemed sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech for championing the cause of cancer research and patient well-being. Empower yourself with more knowledge and stay updated with the latest in cancer care. Dive…

Dive deep into the world of EGFR TKIs with Dr. Millie Das and Angel Qin in this enlightening session from the 2022 Targeted Therapies Forum. Explore the efficacy of EGFR TKIs, their potential combinations, and their strategic use post-chemotherapy to optimize treatment outcomes in cancer patients. A heartfelt acknowledgment to our generous sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech for their unwavering support in advancing cancer research and patient care. Equip yourself with the latest advancements in cancer therapy. Explore further at http://cancerGRACE.org/. Join our dedicated community and be part of the conversation at https://cancergrace.org/forum.

Explore the frontier of ALK+ NSCLC treatments in this in-depth session from the 2022 Targeted Therapies Forum, led by the esteemed Dr. Millie Das. As ALK+ NSCLC continues to be a central topic in oncological research, this video sheds light on the most promising emerging therapies and their potential implications for patient care. Special thanks to our dedicated sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, for their continued support in pushing the boundaries of cancer treatment and research. Stay updated with the latest breakthroughs in cancer treatment and research. Dive deeper at http://cancerGRACE.org/. Engage with a community of…

Addressing the challenges of ALK TKIs, this insightful session from the 2022 Targeted Therapies Forum is brought to you by the distinguished Dr. Millie Das. In the vast landscape of cancer treatments, ALK TKIs have shown significant promise, but like all therapies, they come with their considerations. Huge appreciation to our generous sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Their commitment drives progress in the ever-evolving realm of oncology. For a deeper dive into the advancements and discussions in cancer treatment, explore http://cancerGRACE.org/. Engage and share with our expert community at https://cancergrace.org/forum.

Dive into the dynamic world of ALK+ NSCLC treatment with Dr. Millie Das, a prominent figure in oncology, as she unveils the journey and rigorous processes behind the approval of current medications. Hosted by the 2022 Targeted Therapies Forum, this session offers a rich blend of insight and knowledge. Heartfelt thanks to our esteemed sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, whose dedication fuels the advancement in cancer care. Stay updated with the latest in cancer treatments and join our growing community. Discover more at http://cancerGRACE.org/. For engaging discussions and shared experiences, head over to https://cancergrace.org/forum.

Understanding ALK+ NSCLC? Dive into this illuminating session as Dr. Millie Das, a renowned oncologist, breaks down what ‘ALK+’ signifies in the context of lung cancer. This special segment is part of the 2022 Targeted Therapies Forum, connecting you with the latest insights in oncology. Our deepest appreciation to our dedicated sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Your support continually pushes the boundaries of cancer research and patient care. Stay abreast of the evolving world of cancer treatments. Learn more and enrich your knowledge at http://cancerGRACE.org/. Engage, ask, and converse with our global community at https://cancergrace.org/forum.

Targeted Therapies Forum 2022, Breakout Session: Dr. Angel Qin discusses the use of Patritumab Deruxtecan for EGFR+ NSCLC. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Angel Qin looks at the Chrysalis-2 Trial, which studied the combination of Amivantamab and Lazertinib for EGFR+ NSCLC Patients with Progression on Osimertinib and platinum-based chemo. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Targeted Therapies Forum 2022, Breakout Session: Dr. Angel Qin discusses next steps if Osimertinib stops working. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Targeted Therapies Forum 2022, Breakout Session: Dr. Angel Qin examines the various TKIs for EGFR+ NSCLC, and their side effects. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.